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Abstract 
 
 
 Cartilage Tissue Engineering. Joint pain and functional impairment due to 
cartilage damage from osteoarthritis and other means is a major source of disability 
for adults the world over. Cartilage is an avascular tissue with a very limited capacity 
for self repair. Current medical and surgical approaches to cartilage repair also have 
limited efficacy, and in all cases fail to completely restore a normal, healthy cartilage 
phenotype. Tissue engineering is a relatively new approach to cartilage repair that 
seeks to fabricate a replacement tissue, indistinguishable from healthy, native tissue.  
 
   The basic idea of the tissue engineering approach is to seed tissue 
synthesizing cells into a shapeable, biocompatible/bioabsorbable scaffold that serves 
as a temporary extracellular matrix with a localized source of bioactive molecules to 
direct the development of new tissue.  The challenge of tissue engineering is to 
identify cells, scaffolds, and growth conditions that will be optimal for tissue 
regeneration. The goal of the current studies was to evaluate one aspect of all three of 
the major components of cartilage tissue engineering: cell source, scaffolding 
material and preparation, and controlled growth factor delivery. 
 
 We evaluated the chondrogenic potential of human nasal chondrocytes grown 
in calcium alginate in an in vivo culture system, the potential of computer-aided 
design and injection molding with calcium alginate to reliably reproduce complex 
geometries with high dimensional tolerances, and the potential for the controlled 
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release of TGF-β1 from calcium alginate modified by the covalent addition of a 
recently discovered TGF-β binding peptide. 
 
 We found that adult human nasal chondrocytes show significant chondrogenic 
potential when grown within an alginate scaffold.  We also found that alginate is 
readily amenable to an injection molding process that utilizes precision made molds 
from computer-aided design and solid free form fabrication, allowing for the 
fabrication of tissue engineered constructs with very precise shape fidelity. 
Additionally, we found that calcium alginate could be reliably modified by the 
covalent addition of peptides, and that the addition of a newly discovered TGF-β 
binding peptide delayed the release of pre-loaded TGF-β1. Together these results 
show some of the encouraging prospects for cartilage tissue engineering.    
 
 `Menière’s Syndrome. Menière’s syndrome is an inner ear disorder 
characterized by idiopathic endolymphatic hydrops with associated periodic tinnitus, 
vertigo, and progressive sensorineural hearing loss. It affects approximately 0.2% of 
the population, for whom it can be quite devastating. In addition to progressive 
hearing loss people with Menière’s syndrome are prone to sudden attacks of vertigo 
and tinnitus that are severe enough that they can lead to falls and potentially serious 
injury. People subject to frequent attacks are unable to drive, with obvious 
consequences on standard of living.   
 
 vii
 In the current studies we evaluated the standard animal model of Menière’s 
syndrome by comparing cochlear turn specific hearing thresholds and the degree of 
hydrops in that turn. A positive correlation between these had previously been 
established in the study of human temporal bones from people with Menière’s 
syndrome, but had not been reported in the animal model.  
 
 We also evaluated the potential of aminoguanidine, a relatively specific 
inhibitor of the inducible isoform of nitric oxide synthase, as a neuroprotective 
therapeutic agent for preservation of hearing in animals with surgically induced 
endolymphatic hydrops. 
 
 We found, for the first time, a partial correlation between cochlear turn 
specific hydrops and hearing thresholds in the most commonly used animal model of 
Menière’s syndrome, helping to validate the utility of this animal model for future 
studies. We also found that aminoguanidine did indeed partially preserve hearing in 
animals with surgically induced Menière’s syndrome. This encouraging result appears 
to be the first report of a medical intervention protective against hearing loss in an 
animal model of Menière’s syndrome, and may help us to understand the etiology 
pathology seen in Menière’s syndrome.  
 viii
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Introduction 
 
 Cartilage Structure. Articular cartilage, the tissue that lines all diarthrodial 
joints (freely moving joints), functions as a low friction, wear-resistant tissue that 
bears and distributes load. It is composed of sparsely scattered chondrocytes in a 
dense extracellular matrix (ECM) composed primarily of type II collagen, 
proteoglycans, and water. Other classes of molecules make up a minor, poorly 
defined, component of cartilage; these include proteins, lipids, phospholipids, and 
various other minor collagens. The chondrocytes, the only cellular component of 
cartilage, make up only about 5-10% of the wet weight of cartilage, but their 
metabolism is entirely responsible for maintaining the appropriate composition of the 
ECM. Articular cartilage is endowed with its specialized mechanical properties by the 
highly organized nature of the ECM, which can be structurally and functionally 
divided into four distinct zones: the superficial zone, the middle zone, the deep zone, 
and the zone of calcified cartilage. Each of these zones has a distinct organization and 
function in native cartilage.  
 
The superficial zone is the articulating surface that provides a smooth gliding 
surface and resists sheer. This zone makes up approximately 10-20% of the thickness 
of articular cartilage. It has the highest collagen content of the zones, with densely 
packed fibrils aligned parallel to the articular surface1. The superficial zone has the 
lowest compressive modulus and will deform approximately 25 times more than the 
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middle zone. The chondrocytes in this layer, characterized by an elongated 
appearance, preferentially express proteins that have lubricating and protective 
functions and secrete relatively little proteoglycan8. Among the proteins involved in 
surface lubrication, superficial zone protein (SZP), also known as lubricin, has been 
identified as a functionally important molecule. SZP has an extremely low coefficient 
of friction, and together with hyaluronic acid in the synovial fluid creates an almost 
frictionless articulation. Additionally, the ability to synthesize SZP has been used 
phenotypically to distinguish superficial zone chondrocytes from those in the deeper 
layers9-10.   
 
The middle zone comprises about 40-60% of the articular cartilage volume. 
This zone has a higher compressive modulus that the superficial zone and a less 
organized arrangement of collagen fibrils. The fibrils are thicker, more loosely 
packed, and aligned obliquely to the articular surface. The chondrocytes in this layer 
are more rounded, and do not secrete SZP.  
 
The deep zone makes up about 30% of the cartilage and consists of large 
diameter collagen fibrils oriented perpendicular to the articular surface. This layer 
contains the highest proteoglycan and lowest water concentration, and has the highest 
compressive modulus. The chondrocytes are typically arranged in columnar fashion 
parallel to the collagen fibrils and perpendicular to the joint line. The deep zone is 
partially calcified, and the calcified layer is distinguished histologically by a 
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boundary with non-calcified cartilage called the tidemark. The calcified zone 
represents residue from the secondary center of ossification in the epiphysis of the 
underlying bone. Its chondrocytes frequently exhibit hypertrophy, as is seen in 
endochondral bone formation. These cells can synthesize type-X collagen, can calcify 
their extracellular matrix, and are rich in alkaline phosphatase. When cartilage 
degenerates, as in osteoarthritis, the calcified zone extends further into the deep zone 
and new tidemarks appear. This is of substantial clinical importance, because with 
calcification of the extracellular matrix the unique properties of cartilage, especially 
its ability to recover from deformation, are lost. 
 
Due to the nature of the ECM, cartilage is a highly hydrated tissue, with water 
making up between 70%-80% of its wet weight. The ECM makes up 90% of the dry 
weight of cartilage, and more than half of that weight is made up of proteoglycans. 
Proteoglycans are composed of a large core protein, and covalently bound, sulfated 
glycosaminoglycan (GAG) chains. In cartilage, a typical large proteoglycan has 100 
long chondroitin sulfate chains and 50 much shorter keratin sulfate chains. These 
GAG chains account for approximately 90% of the molecular weight of the 
proteoglycan12. Proteoglycans are entangled and compacted within the collagen 
interfibrillar space, which helps to maintain a porous, permeable solid matrix. The 
charged sulfate groups on proteoglycan GAG chains exhibit electrostatic repulsion, 
and allow substantial hydration. Proteoglycan swelling in cartilage is limited by the 
collagen fibril network, which restricts proteoglycan size to as little as 20% of its 
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potential.1 The hydrated proteoglycans account for the ability of articular cartilage to 
resist compressive loads. The collagen mesh, in turn, allows the tissue to resist 
tension and shear forces.2 
 
 
 Cartilage Damage and Osteoarthritis. Articular cartilage is a remarkably 
durable tissue that provides for almost frictionless motion between the articulating 
surfaces of diarthrodial joints, while protecting the underlying bones from the 
mechanical stresses of normal joint use. The architecture of the ECM and the 
resulting substantial hydration endow cartilage with its ability to cushion the 
underlying subchondral bone during loading. Chondrocytes continually synthesize, 
incorporate and degrade ECM proteins, permitting much of the cartilage matrix to 
undergo turnover and maintenance. Circumstances that impair chondrocyte function 
can disrupt the balance of synthesis and catabolism in favor of cartilage degradation, 
which over time can lead to osteoarthritis (OA).  
 
OA afflicts more than 20 million people in the United States, and is the single 
leading cause of disability in adults.13 Osteoarthritis is increasingly common with 
advancing age. About 10% of adults over the age of 50, 50% of adults over the age 
65, and nearly all people over the age of 75 have some features of osteoarthritis.14-17 
The total annual societal cost for arthritis, has been estimated at over 2% of the 
United States gross domestic product, making the understanding of the 
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pathophysiology and the search for novel treatments of paramount importance in 
health care science.18 
 
There are three main types of cartilage injury: matrix disruption, partial 
thickness defects, and full thickness defects. Matrix disruption occurs from blunt 
trauma, such as dashboard injuries in automobile accidents. The ECM is damaged, 
but if the injury is not extreme, the remaining viable chondrocytes will increase their 
synthetic activity to repair the tissue. Partial thickness defects demonstrate disruption 
of the cartilage surface, but this does not extend to the subchondral bone. 
Immediately following the injury, nearby cells begin to proliferate, but for reasons 
that remain unclear, cellular attempts to fill the defect cease before it is repaired. It is 
widely speculated that because of entrapment in the relatively rigid ECM 
chondrocytes are unable to sufficiently proliferate or migrate to mount an effective 
wound healing response. Full thickness defects arise from damage that transverses the 
entire cartilage thickness and penetrates the subchondral bone. In this case, the defect 
is filled with a fibrin clot and a classic wound healing response ensues. With this type 
of injury, unlike the others, there is access to a population of progenitor cells from the 
bone marrow which can migrate to fill the defect19. These cells, however, usually 
cause replacement of the fibrin clot with tissue intermediate between hyaline and 
fibrocartilage, making a tissue that is usually quite a bit less stiff and more permeable 
than native cartilage. Consequently this tissue often degrades over a period of 
months20-21 . 
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Whatever the initial etiology, the end-stage of articular cartilage disease, with 
clinical characteristics including joint pain, stiffness, dysfunction, and deformity, as 
well as the radiographic manifestations of joint space narrowing, subchondral 
sclerosis, and osteophyte formation, are easily recognized. However, signs and 
symptoms in earlier stages, when treatment may alter disease course, are more 
elusive. Understanding the basic science of cartilage and the changes that occur in 
OA is imperative to develop novel strategies to diagnose and treat this disorder. 
 
The specialized architecture and limited repair capacity of articular cartilage 
coupled with the high physical demands on this tissue make it exceedingly difficult to 
treat medically. There is currently no regimen, either pharmacologic or surgical, that 
is capable of restoring damaged cartilage to its normal phenotype. The tissue 
engineering approach to cartilage repair attempts to overcome these difficulties by 
delivering ECM producing cells entrapped in a space-filling matrix.  
 
 Tissue Engineering. Tissue engineering is an interdisciplinary science 
that combines basic principles of biology, chemistry, physics, and engineering to 
construct living tissues from their cellular components. A major goal of tissue 
engineering is the medical application of fabricated tissues for the augmentation or 
replacement of congenitally defective, impaired, injured, or otherwise damaged 
human tissue22. There has been significant tissue engineering research covering a 
wide variety of tissues, including: bladder, aorta, skin, breast, muscle, bone, cartilage, 
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and tendon.23-29 Regardless of the tissue of interest, the tissue engineering approach 
always combines three key elements: cells to produce the new tissue, a 
biocompatible/bioabsorbable scaffold to support and localize the cells, and bioactive 
molecules to direct tissue development. 
 
 
 Cells for cartilage repair and tissue engineering. Cell-based therapy is a 
promising approach to cartilage regeneration. Different cell types offer different 
potential advantages and challenges. There has been research looking at the tissue 
engineering potential of primary chondrocytes, chondrocytic cell lines, adult 
mesenchymal stem cells, and embryonic stem cells. The most obvious source for cells 
that can regenerate cartilage is the cartilage itself. Chondrocytes, the cells which 
reside within and maintain and remodel cartilage, are readily harvested, but are 
limited in number, and expansion in standard monolayer culture tends to lead to de-
differentiation, with loss of the chondrocyte phenotype. Additionally, donor site 
morbidity can be a significant issue when harvesting adult chondrocytes.  
 
 Clonal chondrocyte-like cell lines derived from chondrosarcomas or 
immortalization of primary cells with SV40 large T antigen provide an essentially 
limitless supply of cells with no associated harvesting morbidity, but recent 
microarray gene expression profiling indicates that while several popular lines (HCS-
2/8, SW1353, and C-20/A4) do express cartilage markers, they differ significantly 
from primary cells.30-32 Embryonic stem cells have been studied less in this 
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application, but are widely believed to have significant potential. As with all 
applications with embryonic stem cells, technical expertise, availability, and ethical 
issues all provide obstacles. 
 
 Scaffolds for cartilage tissue engineering. The function of a tissue 
engineering scaffold is to provide a temporary structure while cells seeded within this 
biodegradable matrix synthesize new, natural tissue. New tissue regeneration occurs 
during scaffold degradation, with the new tissue taking on the shape and size of the 
original scaffold. Design criteria include controlled biodegradability, suitable 
mechanical strength and surface chemistry, ability to be processed in different shapes 
and sizes, and the ability to regulate cellular activities, such as proliferation and 
differentiation.33 Both natural and synthetic polymers have been fabricated as 
scaffolds for cells in a variety of forms, including fibrous structures, porous sponges, 
woven or non-woven meshes, and hydrogels. 
 
 Hydrogels are cross-linked polymer networks that have the ability to absorb 
large amounts of water, making these materials attractive scaffolds for engineering 
tissues with high water content, such as cartilage. The unique ability of hydrogel 
scaffolds to encapsulate cells rather than promote attachment keeps cells in a 
spherical morphology conducive to maintenance of chondrocyte phenotype. In 
principle, a cell–polymer suspension could be injected into a cartilage defect just 
prior to gelation in situ. This would eliminate a separate cell-seeding step post-
 xx
scaffold fabrication, and potentially minimize the need for invasive surgical 
implantation. However, the technical challenge of maintaining precise polymer/cell 
localization in situ has proven problematic. Alternatively, the cell/polymer suspension 
can be injected into molds of anatomic shapes and then cross-linked to form an 
implantable hydrogel. 
 
 
 Signaling molecules in cartilage regeneration. Signaling molecules, 
including growth factors, cytokines, and non-protein chemical compounds, are 
commonly used to promote tissue growth in cartilage tissue engineering. It is 
bioactive signaling molecules that bind to cell surface receptors, activating 
intracellular pathways that instruct cells to proliferate, differentiate, and synthesize 
extracellular matrix proteins during tissue regeneration. 
 Growth factors shown to have regulatory effects on chondrocytes or stem cells 
for cartilage tissue engineering include members of the TGF-β superfamily, IGFs, 
fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs), and the 
epidermal growth factor (EGF) family. Among these growth factors, TGF-βs are the 
most potent inducers of both chondrogenesis in MSCs, and enhancement of cartilage 
ECM synthesis by fully differentiated chondrocytes.34,35-44 
 
 A successful tissue engineering approach to cartilage repair will require 
attention to all three of the major elements of tissue engineering: cell source, scaffold 
design, and delivery of bioactive molecules. 
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Menière’s Syndrome 
 Menière’s syndrome is a disorder of the inner ear which causes episodes of 
vertigo, tinnitus (ringing in the ear), a feeling of fullness or pressure in the ear, and 
fluctuating, progressive sensorineural hearing loss. A typical attack of Menière’s 
syndrome is preceded by fullness in one ear. Hearing fluctuation or changes in 
tinnitus may also precede an attack. A Menière’s episode generally involves severe 
vertigo (spinning), imbalance, nausea and vomiting. The average attack lasts two to 
four hours. Following a severe attack, most people find that they are exhausted and 
must sleep for several hours. There is a large amount of variability in the duration of 
symptoms. Some people experience brief episodes of unsteadiness, and others have 
constant unsteadiness. Menière’s episodes may occur in clusters; that is, several 
attacks may occur within a short period of time. However, years may pass between 
episodes. Between the acute attacks, most people are free of symptoms or note mild 
imbalance and tinnitus.  
 Menière’s syndrome affects roughly 0.2% of the population. It usually starts 
confined to one ear, but it often extends to involve both ears over time so that after 30 
years, more than 50% of patients with Menière’s syndrome have bilateral disease.45  
In almost all cases, a progressive sensorineural hearing loss occurs in the affected 
ears. This tends to follow a typical course, with low-frequency sensorineural loss 
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initially, progressing to the classic peaked audiogram seen with low and high 
frequency loss, and finally a flat audiogram, as hearing is lost across all frequencies.46 
 The exact cause of an acute attack is unknown, but most researchers believe it 
results from fluctuating pressure of the fluid within the inner ear.47 Within the inner 
ear there is a system of membranes, called the membranous labyrinth which contains 
a fluid called endolymph. The histophathologic hallmark of Menière’s syndrome is 
ballooning of Reisner’s membrane within the membranous labyrinth from excess 
fluid pressure within the endolymph. This process is called endolymphatic hydrops.  
 It is not currently known why people with Menière’s syndrome develop 
endolymphatic hydrops, but it is presumed to be either from blockage of the 
endolymph drainage system, the endolymphatic duct and sac, or by excess 
endolymph production by the stria vascularis. The animal model used for studying 
Menière’s syndrome is endolymph obstruction in the albino guinea pig, created by 
surgical destruction of the endolymphatic duct and sac, leading to an inability of the 
inner ear to drain endolymph. These animals do show a progressive sensorineural 
hearing loss, but it is unknown if they experience tinnitus or vertigo. As with most 
animal models some controversy exists as to how well the symptoms and 
pathogenesis of the target disease are replicated.48  
 There is currently no curative medical treatment for Menière’s syndrome. The 
mainstay of treatment involves medications to palliate the symptoms vertigo. 
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Establishment of treatments to alter the course of the disease will require a better 
understanding of the pathogenesis. 
 
 
 
 
 xxiv
References 
 
1. Mow VC, Proctor CS, Kelly MA. Biomechanics of articular cartilage. In: Nordin  
    M, Frankel VH, editors. Basic biomechanics of the musculoskeletal system.  
    Philadelphia7 Lea & Febiger; 
    1989. p. 31– 57. 
 
2. Maroudas A, Bayliss MT, Venn MF. Further studies on the composition of human 
    femoral head cartilage. Ann Rheum Dis. 1980;39:514-23. 
 
3. Swann DA, Sotman S, Dixon M, Brooks C. The isolation and partial    
    characterization of the major glycoprotein (LGP-1) from the articular lubricating   
    fraction from bovine synovial fluid. Biochem J. 1977;161:473-85. 
 
4. Poole AR. Cartilage in health and disease. In: Koopman WJ, editor. Arthritis 
    and allied conditions. A textbook of rheumatology. 14th ed. Volume 1.   
    Philadelphia: 
    Lippincott Williams and Wilkins; 2001. p 226-84. 
 
5. Kempson GE, Muir H, Pollard C, Tuke M. The tensile properties of the cartilage 
    of human femoral condyles related to the content of collagen and      
    glycosaminoglycans. Biochem Biophys Acta. 1973;297:456-72. 
 
 xxv
6. Mitrovic D, Quintero M, Stankovic A, Ryckewaert A. Cell density of adult human 
    femoral condylar articular cartilage. Joints with normal and fibrillated 
    surfaces. Lab Invest. 1983;49:309-16. 
 
7. Mitrovic D, Quintero M, Stankovic A, Ryckewaert A. Cell density of adult human 
    femoral condylar articular cartilage. Joints with normal and fibrillated 
    surfaces. Lab Invest. 1983;49:309-16. 
 
8. Wong M, Wuethrich P, Eggli P, Hunziker E. Zone-specific cell biosynthetic     
    activity in mature bovine articular cartilage: a new method using confocal   
    microscopic stereology and quantitative autoradiography. J Orthop Res   
    1996;14(3):424– 32. 
 
9. Schumacher BL, Hughes CE, Kuettner KE, Caterson B, Aydelotte MB.   
    Immunodetection and partial cDNA sequence of the proteoglycan, superficial zone   
    protein, synthesized by cells lining synovial joints. J Orthop Res 1999;17(1):110–   
    20. 
 
10. Schumacher BL, Block JA, Schmid TM, Aydelotte MB, Kuettner KE. A novel  
      proteoglycan synthesized and secreted by chondrocytes of the superficial zone of  
      articular cartilage. Arch 10. Biochem Biophys 1994;311(1):144–52. 
 
 xxvi
11. Mankin HJ, Mow VC, Buckwalter JA, Iannotti JP, Ratcliffe A. Articular cartilage   
      structure, composition, and function. In: Buckwalter JA, Einhorn TA, Simon SR,   
      editors. Orthopedic basic science: biology and biomechanics of the  
      musculoskeletal system. Rosemont (IL)7 American Academy of Orthopaedic  
      Surgeons; 1999. p. 444– 70. 
 
12. Ateshian GA, Wang H. Rolling resistance of articular cartilage due to interstitial  
      fluid flow. Proc Inst Mech Eng [H] 1997;211(5):419– 24. 
 
13. CDC. Prevalence of disabilities and associated health conditions among adults in  
      the United States, 1999. MMWR 2001;50:120-125  
 
14. Felson DT. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev   
      988;10:1– 28. 
 
15. Peyron, Jo Epidemiological aspects of osteoarthrits. Scand J Rheumatol Suppl 
      1988. 77: p. 29-33. 
 
16. Peyron, Jo Clinicalfeatures of osteoarthrits, difuse idiopathic skeletal 
      hyperostosis, and hypermobilty syndromes. Curr Opin Rheumatol, 1991. 3(4): p. 
      653-61. 
 
 xxvii
17. Bland, J.H. and S.M. Cooper Osteoarthrits: a review of the cell biology involved      
      and evidence for reversibilty. Management rationally related to known genesis     
      and pathophysiology. Semin Arthritis Rheum, 1984. 14(2): p. 106-33. 
 
18. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1:  
      the disease and its risk factors. Ann Intern Med 2000;133(8):635– 46. 
 
19. Buckwalter JA. Articular cartilage: injuries and potential for healing. J Orthop  
      Sports Phys Ther 1998;28:192-202. 
 
20. Hunziker EB. Growth-factor-induced healing of partial thickness defects in adult  
      articular cartilage. Osteoarthritis Cartilage 2001;9:22-32. 
 
21. Hunziker EB, Rosenberg LC. Repair of partial thickness defects in articular  
      cartilage: cell recruitment from the synovial membrane. J Bone Joint Surg Am  
      1996;78:721-33. 
 
22. Woolverton CJ, Fulton JA, Lopina ST, Landis WJ. Mimicking the natural tissue    
      environment. In: Lewandrowski K-U, Wise DL, Trantolo DJ, Gresser JD, 
      Yaszemski MJ, Altobelli DE, editors. Tissue engineering and biodegradable  
      equivalents: scientific and clinical applications. New York7 Marcel Dekker;  
    2002. p. 43– 75. 
 xxviii
 
23. Pariente JL, Kim BS, Atala A. In vitro biocompatibility assessment of naturally  
      derived and synthetic biomaterials using normal human urothelial cells. J Biomed  
      Mater Res 2001;55:33–9. 
 
24. Shum-Tim D, Stock U, Hrkach J, Shinoka T, Lien J, Moses M, et al. Tissue  
      engineering of autologous aorta using a new biodegradable polymer. Ann Thorac 
      Surg 1999;68:2298–305. 
 
25. Vaccariello MA, Javaherian A, Parenteau N, Garlick JA. Use of skin equivalent   
      technology in a wound healing model. In: Morgan JR, Yarmush ML, editors. 
      Methods in molecular medicine: tissue engineering methods and protocols, Vol.  
      Totowa, New Jersey Humana Press; 1999. p. 391– 405. 
 
26. Cao YL, Lach E, Kim TH, Rodriguez A, Arevalo CA, Vacanti CA. Tissue-  
       engineered nipple reconstruction. Plast Reconstr Surg 1998;102:2293– 8. 
 
27. Vandenburgh H, Shansky J, Del Tatto M, Chromiak J. Organogenesis of skeletal   
      muscle in tissue culture. In: Morgan JR, Yarmush ML, editors. Methods in 
      molecular medicine: tissue engineering methods and protocols, Vol. 18. Totowa,     
      New Jersey Humana Press; 1999. p. 217–25. 
 
 xxix
28. Tubo R, Binette F. Culture and identification of autologous human articular  
      chondrocytes for implantation. In: Morgan JR, Yarmush ML, editors. Methods in     
      molecular medicine: tissue engineering methods and protocols, Vol. 18. Totowa,   
      New Jersey7 Humana Press; 1999. p. 205– 15. 
 
29. Isogai N, Landis WJ, Kim TH, Gerstenfeld LC, Upton J, Vacanti JP. Formation of  
      phalanges and small joints by tissue engineering. J Bone Joint Surg  
      1999;81A:306–16. 
 
30. Finger F, Schorle C, Soder S, et al. Phenotypic characterization of human     
      chondrocyte cell line C-20/A4: a comparison between monolayer and alginate     
      suspension culture. Cells Tissues Organs 2004; 178:65–77. 
 
31. Gebauer M, Saas J, Sohler F, et al. Comparison of the chondrosarcoma cell line   
      SW1353 with primary human adult articular chondrocytes with regard to their   
      gene expression profile and reactivity to IL-1beta. Osteoarthritis Cartilage 2005;  
     13:697–708. 
 
32. Saas J, Lindauer K, Bau B, et al. Molecular phenotyping of HCS-2/8 cells as 
      an in vitro model of human chondrocytes. Osteoarthritis Cartilage 2004;12:924–  
      934. 
 
 xxx
33. Kuo CK, Tuan RS. Tissue engineering with mesenchymal stem cells. Ieee    
      Engineering In Medicine And Biology Magazine 2003; 22:51–56. 
 
34. Li WJ, Tuli R, Okafor C, et al. A three-dimensional nanofibrous scaffold for 
      cartilage tissue engineering using human mesenchymal stem cells. Biomaterials 
      2005; 26:599–609. 
 
35 Stevens MM, Marini RP, Martin I, et al. FGF-2 enhances TGF-beta1-induced 
     periosteal chondrogenesis. J Orthop Res 2004; 22:1114–1119. 
 
36 Lee JE, Kim KE, Kwon IC, et al. Effects of the controlled-released TGF-beta 1 
     from chitosan microspheres on chondrocytes cultured in a collagen/chitosan/ 
     glycosaminoglycan scaffold. Biomaterials 2004; 25:4163–4173. 
 
37. Barbero A, Grogan S, Schafer D, et al. Age related changes in human articular 
      chondrocyte yield, proliferation and post-expansion chondrogenic capacity. 
      Osteoarthritis Cartilage 2004; 12:476–484. 
 
38 Tay AG, Farhadi J, Suetterlin R, et al. Cell yield, proliferation, and postexpansion 
     differentiation capacity of human ear, nasal, and rib chondrocytes. Tissue 
     Eng 2004; 10:762–770. 
 
 xxxi
39 Hegewald AA, Ringe J, Bartel J, et al. Hyaluronic acid and autologous synovial 
     fluid induce chondrogenic differentiation of equine mesenchymal stem cells: a 
     preliminary study. Tissue Cell 2004; 36:431–438. 
 
40 Glowacki J, Yates K, Maclean R, Mizuno S. In vitro engineering of cartilage: 
     effects of serum substitutes, TGF-beta, and IL-1alpha. Orthod Craniofac Res 
     2005; 8:200–208. 
 
41. Vunjak-Novakovic G, Meinel L, Altman G, Kaplan D. Bioreactor cultivation of 
      osteochondral grafts. Orthod Craniofac Res 2005; 8:209–218. 
 
42. Chua KH, Aminuddin BS, Fuzina NH, Ruszymah BH. Interaction between 
      insulin-like growth factor-1 with other growth factors in serum depleted 
      culture medium for human cartilage engineering. Med J Malaysia 2004; 59 
     (Suppl B):7–8. 
 
43. Indrawattana N, Chen G, Tadokoro M, et al. Growth factor combination for 
      chondrogenic induction from human mesenchymal stem cell. Biochem 
      Biophys Res Commun 2004; 320:914–919. 
 
44. Wang Y, Kim UJ, Blasioli DJ, et al. In vitro cartilage tissue engineering with 3D 
      porous aqueous-derived silk scaffolds and mesenchymal stem cells. Biomaterials 
 xxxii
      2005; 26:7082–7094. 
45. Stahle J, Friberg U, Svedberg A. Long-term progression of Meniere's disease.  
      Acta Otolaryngol (Stockh) 1991:Suppl 485:75-83 
46. Kinney SE, Sandridge SA, Newman CW. Long-term effects of Meniere’s disease      
      on hearing and quality of life. Am J Otol 1997 Jan;18(1):67-73.HAVIA M,  
47. Kentala E. Progression of symptoms of dizziness in Meniere’s  disease. Arch   
     Otolaryngol Head Neck Surg 2004;130:431-5. 
48. Kimura RS, Schuknecht JF. Membranous hydrops in the inner ear of guinea  
      pig after obliteration of the endolymphatic sac. Pract Otorhinolaryngol  
      1965;27:343-5. 
 1
CHAPTER I 
 
 
 
 
 
 
 
 
 
 
 
 
FABRICATION OF TISSUE ENGINEERED CARTILAGE 
UTILIZING HUMAN NASAL SEPTAL CHONDROCYTES AND 
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Abstract 
 
 
 Objectives/Hypothesis. The goal of the current study was to evaluate the 
chondrogenic potential of first passage human nasal septal chondrocytes grown in 
injection molded calcium alginate constructs cultured in vivo in athymic mice. 
 
 Method. Molds of an implantable silicon nasal bridge were cast using a 
commercial silastic ERTV mold making kit. Human nasal septal chondrocytes were 
liberated by collagenase digestion, suspended in 2% alginate mixed with CaSO4 (0.2 
g/ml) and injected into prepared molds. Un-molded constructs were implanted 
subcutaneously in the dorsum of athymic mice, and recovered for biochemical, 
histological, and biomechanical analysis at 2, 4, 6, 12, and 23 weeks. 
 
 Results. Recovered constructs demonstrated reasonably good shape fidelity 
and progressively increasing extracellular matrix deposition, as determined by 
hydroxyproline and glycosaminoglycan content. Consistent with progressively 
developing extracellular matrix, equilibrium compressive modulus also continually 
increased. Safranin-O staining showed progressively increasing proteoglycan 
production. Consistent with a cartilage phenotype, almost all the collagen produced 
was type II collagen, as determined by collagen ELISA. 
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 Conclusions. Preliminary data suggest that first passage human nasal septal 
chondrocytes exhibit good chondrogenic potential in calcium alginate constructs 
cultured in an in vivo system. Because we used first passage cells it was possible to 
make constructs for implantation that were 80 times more massive than the original 
septal biopsy from which the cells were harvested: a necessary feature for clinical 
applications. These results indicate that human nasal septal chondrocytes have 
potential utility as a cell source for the engineering of cartilage replacements.  
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Introduction 
 
 Annually there are over one million surgeries in the United States that involve 
the replacement of either bone or cartilage1. Craniofacial deformities pose a special 
set of difficulties for the reconstructive surgeon. Whatever the cause of the defect, be 
it congenital anomaly or trauma the standard approach to repair is the same. Current 
clinical practice is to effect a repair using either autologous bone and cartilage or any 
of a variety of synthetic materials2-4. Common donor sites for autologous bone to be 
used in a reconstruction include calvarial, iliac, and costal areas5-6. Cartilage is 
commonly harvested from auricular, costal, and septal sites7-9.  
 
 Autologous grafting with bone or cartilage is still the standard of care, and is 
the most common approach10. There are, though, a number of inherent difficulties. 
For any reasonable size defect obtaining sufficient donor site material is associated 
with an often unacceptable level of morbidity11-13. This often makes it necessary to 
have multiple donor sites used for harvest and can require multiple operations. It also 
adds the technical difficulty of needing to combine several different tissue harvests 
into a single unit for reconstruction. Synthetic materials avoid the problems of donor 
site morbidity and tissue availability, but come with their own set of problems. 
Synthetic materials can feel unnatural under the skin, and are somewhat more prone 
to protrusion through the skin and an increased risk for infection15-16. 
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Given the current limitations in available clinical options for the treatment of 
structural craniofacial lesions, the ability to replace damaged or missing tissue with 
an engineered replacement tissue has the potential to be a valuable new treatment 
modality. The tissue engineering approach is to combine a space filling matrix with 
cells and growth factors in a manner that will encourage new tissue growth. Ideally, 
the initially seeded matrix will be reabsorbed at the same rate that new tissue is 
formed, so that ultimately the patient will be left with a tissue replacement in the 
exact shape of the original matrix, but indistinguishable from native tissue. This 
approach has the potential to combine the best aspects of autologous grafting and 
synthetic prosthesis. There is no donor site morbidity, material is abundant, and with 
the reabsorption of the original matrix there should not be the increased risk of 
protrusion or infection seen with synthetic materials.  
 
 Alginate, a linear co-polymer hydrogel of mannuronic acid and guluronic 
acid, has been known for many years to have value for the three dimensional culture 
of chondrocytes. Chondrocytes grown in standard monolayer culture tend to 
dedifferentiate into a fibroblastic phenotype. Chondrocytes grown in three 
dimensional alginate culture have been shown to maintain their chondrocyte 
phenotype, and continue to produce proteoglycans17-20. There are several properties of 
alginate that make it appealing as a tissue engineering matrix in addition to its known 
value for chondrocyte culture. It has already been established to be biocompatible21, 
and because of its ability to crosslink and gel in the presence of divalent cations can 
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be precisely shaped in complex geometries. This has been previously demonstrated 
with acellular constructs22 and using freshly harvested bovine articular 
chondroctyes23.  
 
 An essential component of tissue engineering is the combining of cells with a 
biocompatible matrix. The ideal cell source for tissue engineering of cartilage is still 
unknown. Possible cell sources that have been considered include articular 
chondrocytes, auricular chondrocytes, nasal septal chondrocytes, perichondrial cells, 
and mesenchymal stem cells. Nasal septal chondrocytes are intriguing as a cell source 
for several reasons. They are already primary chondrocytes, so there is no need to 
orchestrate a precise differentiation, and they can be harvested with a minimum of 
donor site morbidity. 
 
 The goal of the current study was to evaluate the chondrogenic potential of 
human nasal septal chondrocytes when used in injection molded calcium alginate 
constructs grown in vivo on the dorsum of athymic mice.  
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Methods And Materials 
 
  
 Chondrocyte Isolation. Chondrocytes were isolated from human nasal septa 
obtained from septoplasty patients at Englewood hospital, Englewood, NJ. A total of 
30 septa were used. Donor age ranged between 16-62 years and had a mean age of 32 
± 6 years. Twenty-one septa were from women and nine from men. Upon surgical 
excision all septa were stored immediately in sterile 50 ml conical tubes (BD 
Biosciences, Bedford, MA) containing 30 mls of sterile Hamm’s F-12 culture media 
(Gibco, Grand Isand, NY) with 100 μg/ml antibiotic/antimycotic (10,000 U/ml 
penicillin G sodium, 10,000 µg/ml streptomycin sulfate, and 25 µg/ml amphotericin 
B, Gibco, Grand Island NY).  Excised nasal septa were then shipped by overnight 
mail to the University of Massachusetts Medical School, where all future work was 
done. Immediately upon arrival at the University of Massachusetts individual septa 
were washed thoroughly two times in phosphate buffered saline (PBS, Sigma-
Aldrich, Irvine, CA) supplemented with antibiotic/antimycotic. Washed septa were 
then cut into approximately 0.5 cm2 slices and again washed thoroughly two times in 
PBS with antibiotic/antimycotic. Cartilage slices were then digested enzymatically in 
0.3 % collagenase (Worthington Biochemical Corp, Freehold, N.J.) for approximately 
10 hours. The resultant digest was filtered through a sterile 100 μm cell strainer (BD 
Biosciences, Bedford, MA,) in order to separate the liberated chondrocytes from any 
remaining undigested cartilage. Recovered cells were washed thoroughly 2 times in 
sterile PBS supplemented with antibiotic/antimycotic, pelleted by centrifugation at 
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7000 rpm and resuspended in sterile Hamm’s F-12 culture media. Resuspended cells 
were counted on a hemocytometer, and cell viability was determined by the trypan 
blue dye exclusion assay (Sigma-Aldrich, Irvine, CA). Individual septa yielded 
between three hundred thousand and 2 million cells. Only tissue digests that 
demonstrated better then 90% cell viability were used in the study.  
 
 Chondrocyte Culture. Isolated chondrocytes were cultured in standard 
monolayer culture in T-225 culture flasks (BD Biosciences, Bedford, MA), at an 
initial plating density of approximately 1,500 cells per cm2. Culture medium was 
comprised of Hamm’s F-12 culture media with 10% heat inactivated fetal bovine 
serum (FBS, Gibco, Grand Island, NY), 50 μg/ml ascorbate (Sigma-Aldrich, Irvine, 
CA, USA), and 1% antibiotic/antimycotic (10,000 U/ml penicillin G sodium, 10,000 
µg/ml streptomycin sulfate, and 25 µg/ml amphotericin B) (Gibco, Grand Island NY, 
USA). Culture medium was changed every second day and the cells were grown until 
near confluence. Nearly confluent cultures were trypsinized (0.05% trypsin-EDTA, 
Gibco, Grand Island, NY), the cells collected and washed twice in PBS with 
antibiotic/antimycotic, resuspended in Hamm’s F-12 for counting, and replated, again 
in T-225 culture flasks at 1,500 cells per cm2.   
 
 Mold Fabrication. Negative molds for injection were made using a 
commercially available Silastic ERTV mold-making kit (Dow Corning, Midland, 
MI). The silastic and catalyst were mixed 10:1 as per the manufacturer’s instructions 
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and poured into the bottom of a beaker to a height of approximately 1 cm. A non-
implantable model of an implantable silicon nasal bridge (Implantech, Ventura, CA) 
was used as a positive structure for the casting of a negative mold. The silicon nasal 
bridge was coated with petroleum jelly to facilitate its release and embedded in the 
catalyzed silastic until halfway submerged. After 24 hours at room temperature the 
solidified silastic and embedded nasal bridge were coated with a thin layer of 
petroleum jelly all across their top surface except for a small area near one edge. A 
second layer of catalyzed silastic was poured on top and allowed to set at room 
temperature. After 24 hours the silicon nasal bridge was removed and the fully cast 
mold was cleaned and autoclave sterilized.  
 
 Alginate Construct Fabrication. Methods for generating chondrocyte-
seeded alginate constructs were based on previous studies documenting generation of 
cartilage by injection molding (Figure 1). Passage 1 human nasal chondrocytes were 
suspended in filter sterilized 2% low viscosity alginate (FMC Biopolymer, Drammen, 
Norway) in PBS at a seeding density of 50 x 106 cells/ml. Immediately prior to 
injection into the mold the alginate/chondrocyte suspension was combined with a 
solution of autoclave sterilized CaSO4 in PBS (0.25g/ml) by thorough mixing through 
a sterile stopcock (David Scott, MA). The CaSO4 solution was combined with the 
alginate/chondrocyte mixture at a ratio of 0.04 mls of CaSO4 per milliliter of alginate. 
The alginate/chondrocyte/CaSO4  mixture was then injected into the mold using a 3 
ml syringe with an 18.5 gauge needle. After 45 minutes a fully gelled construct was 
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un-molded. Molded constructs were implanted subcutaneously in the dorsum of 
athymic mice and harvested at 2, 4, 6, 12, and 23 weeks. Harvested constructs were 
frozen at -20º C in preparation for histological, biochemical, and biomechanical 
testing.   
 
All animals were treated in accordance with the NIH Guide for the Care and 
Use of Laboratory Animals, and the protocol was approved by the Animal Care 
Committee at the University of Massachusetts Medical School and with the approval 
of the institutional review boards of UMass Medical School and Englewood Hospital. 
      
 
 Histological Analysis. Specimens for histology were fixed in 10% phosphate 
buffered formalin for at least 24 hours and then embedded in paraffin. Paraffin 
embedded engineered tissues were sectioned by microtome and placed on glass 
microscope slides. Sections on slides were de-paraffinized and GAG content 
visualized by staining with Safranin-O.  
 
 Biochemical and Molecular Analysis. Chondrogenic potential of the human 
nasal chondrocytes was assessed by several biochemical measures. Cell number was 
determined by DNA quantification. Extracellular matrix accumulation was assessed 
by quantification of glycosaminoglycans as a marker for proteoglycans, 
hydroxyproline as a marker for total collagen, and a collagen ELISA to determine 
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collagen type and quantity. All biochemical assays were well established techniques 
that have been described elsewhere in detail.  
 DNA Qunatification. Samples for biochemical analysis were digested 
overnight at 60º C in 1 ml of papain digest buffer (0.5 mls papain (Sigma-Aldrich, 
Irvine, CA, USA), 176 mg L-Cysteine (Sigma-Aldrich, Irvine, CA, USA), and 100 
mls PBS with EDTA). DNA was quantified by the PicoGreen DNA assay (Molecular 
Probes, CA) according to the manufacturers instructions. Briefly, 5 μl of the papain 
digest was added to 195 μl of the PicoGreen dye solution in a 96-well plate and the 
contents excited at 485 nm and fluorescence read at 535 nm on an HTS 7000+ 
spectrophotometer (Perkin-Elmer, Wellesley, MA). DNA content was then 
determined by linear interpolation with calf thymus DNA standards. All samples and 
standards were measured in duplicate.  
 
 GAG Quantification. Sulfated GAG content was measured using 1,9-
dimethylmethylene blue dye (DMB) at pH 1.5. This pH assures a sufficiently acidic 
environment that the dye binds to the sulfate groups on glycosaminoglycans, but not 
to the carboxyl groups on alginate24. Aliquots of 50 μls of papain digest were 
combined with 950 μls of DMB and optical density was measured at an absorbance of 
525 nm. GAG content was quantified by quadratic interpolation using chondroitin-6-
sulfate from shark cartilage (Sigma-Aldrich, USA) as a standard.  All samples and 
standards were measured in duplicate. 
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 Hydroxyproline Quantification. Hydroxyproline content was measured by 
acid hydrolysis of samples of papain digests, as described in detail elswhere25-26. 
Briefly, equal volume aliquots of 6N HCL and papain digest were combined and 
incubated overnight at 115°C. Chloramine T hydrate (Sigma-Aldrich, USA) and p-
dimethylamino-benzaldehyde (Ehrlich’s reagent) (Sigma-Aldrich, USA) were added 
to the hydroxylated samples and absorbance was measured at 560 nm on an HTS 
7000+ spectrophotometer (PE Wellesley, MA). Hydroxyproline content was 
determined by linear interpolation using chondroitin 6-sulfate from shark cartilage 
(Sigma-Aldrich) as a standard. All samples and standards were analyzed in duplicate. 
 
 Collagen Type II ELISA. Collagen type was assessed by ELISA using the 
Native Type II Collagen Detection Kit #6009 (Chondrex Inc, Redmond, WA), 
according to the manufacturer’s instructions. First, the collagen molecules were 
extracted from the engineered samples using methods supplied with the ELISA Kit. 
Briefly, samples were lyophilized, and then incubated overnight at 4°C in 3M 
guanidine/0.05M Tris-HCl buffer at pH 7.5 to extract the proteoglycans. The tissue 
was then homogenized and the collagen digested into soluble monomers by 
successive treatment with pepsin and pancreatic elastase. The supplied 96 well 
ELISA plate was incubated overnight with the capture antibody, washed, and loaded 
with the solubulized collagen from the tissue samples and a supplied collagen 
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standard. After a two hour incubation the plate was washed and incubated with the 
supplied biotinylated detection antibody for another two hours, washed again, then 
incubated with streptavidin peroxidase, washed and incubated with the OPD 
chromagen in a H2O2 buffer. The reaction was stopped with 2.5 N sulfuric acid and 
the plate was read on an HTS 7000+ spectrophotometer at 490 nm. Type II collagen 
was quantified by linear interpolation with the supplied collagen standard.  
 
 Total collagen from biochemical assessment of hydroxyproline content was 
compared to the ELISA values to estimate the percent of total collagen that was the 
desired type II. This estimate is based on prior reports that show hydroxyproline to 
make up a consistent percentage of collagen from a wide variety of tissues. In many 
studies this percentage has consistently ranged from 12.3%-14.4%26-29
    
 Biomechanical Analysis. Samples of engineered cartilage for mechanical 
testing were cut into regular right cylindrical discs 1 mm in height and 6 mm in 
diameter using a razor blade and a 6 mm diameter dermal biopsy punch. Discs of 
engineered cartilage were placed in a 6 mm diameter well in an electrically insulated 
confining chamber mounted to a servo-controlled Dynastat mechanical spectrometer 
(IMASS, Hingham, MA) interfaced with a computer. Samples in the confining 
chamber were equilibrated in PBS at pH 7.4 (Gibco, Grand Island, NY) and 
compressed between a porous polyethylene platen and the base of the confining 
chamber. Each sample was compressed in ten sequential steps of 3% static strain to a 
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maximum 30% strain. After each strain step the signal detected by the load cell was 
recorded every 0.5 seconds for 100 seconds. Recorded stress relaxation data was fit to 
a poroelastic model of material behavior to determine the engineered tissue’s 
equilibrium modulus.30-31. 
. 
 
 Statistical Analysis. The statistical changes over time in GAG content, 
hydroxyproline content, DNA content, equilibrium modulus, and hydraulic 
permeability were assessed by computing the Pearson product moment correlation 
coefficient. This value was compared to a critical value for the number of samples 
used in order to determine the statistical significance of any observed changes (p 
value). 
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Results 
 Shape Duplication. The injection molding process allowed for the reasonably 
easy and fast duplication of a desired geometry with reasonably good fidelity 
immediately upon un-molding. Chondrocyte/alginate implants continued to show 
reasonably good shape fidelity through 23 weeks of in-vivo culture (Figure 2). There 
was some early loss in overall volume, presumably due to an initial re-absorption of 
the thin peripheral portions of the alginate construct.  
 
 Histology. On staining with Safranin O after two weeks of in vivo culture 
engineered tissue showed significant alginate matrix containing a large number of 
cells with the characteristic, rounded chondrocyte morphology. Staining of GAGs at 
two weeks was extremely faint, indicating very little extracellular matrix production. 
After four weeks of in vivo culture staining with Safranin-O still shows abundant 
alginate and rounded cells, but also shows small, densely staining islands rich in 
proteoglycans. After 6 weeks of in vivo culture staining with Safranin-O showed large 
densely staining proteoglycan rich areas surrounded by now much smaller areas of 
alginate. By 12 weeks of in vivo culture all of the alginate appears to have been 
reabsorbed and the islands of developing matrix have coalesced into solid, normal 
appearing cartilage, with uniform and significant extracellular matrix (Figure 3). 
Tissue samples for 23 week histology were inadvertently damaged by improper 
processing, so are not presented here. 
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 Biochemistry. Biochemical evaluation of the engineered tissue demonstrated 
that GAG, hydroxyproline, and equilibrium modulus all increased significantly with 
time (p < 0.01). At 23 weeks GAG, hydroxyproline, and equilibrium modulus were 
respectively 68%, 54%, and 44% of average native septal values. DNA did not 
change appreciably over time from what was initially seeded (p > 0.05), consistent 
with the observation that proliferation is inhibited at high cell seeding densities 
(Figures 4-7).  
 
 Quantification of collagen type II by ELISA showed that the developing tissue 
was synthesizing almost exclusively type II collagen, consistent with the cartilage 
phenotype. The lack of type I collagen demonstrates consistency with the cartilage 
phenotype and the lack of scar tissue formation. The amount of collagen identified by 
ELISA was consistent with the indirect quantification by hydroxyproline assessment, 
and ranged from 82%-96% of the total collagen depending on the correction factor 
used (Figure 8).  
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Discussion 
 
 
The goal of the current study was to assess the chondrogenic potential of first 
passage human nasal chondrocytes grown in geometrically complex calcium alginate 
constructs cultured in vivo in athymic mice. After subcutaneous implantation the 
implants developed a gross morphology over time that began to resemble native 
cartilage. The chondrocytes remained metabolically active, producing new 
extracellular matrix. Collagen and proteoglycan content, the two major components 
of the extracellular matrix, increased continuously over time. Consistent with this, the 
equilibrium compressive modulus increased continuously, as the developing tissue 
became stiffer. 
 
 The nasal bridges that were duplicated are very thin along the edges, and in 
these areas shape duplication was not as precise as in thicker areas, or as has been 
demonstrated with larger constructs. For clinical applications, where dimensional 
tolerances of constructs would have to be quite precise, this is potentially a serious 
problem. This difficulty with the duplication of small shapes will be addressed in a 
separate publication by introducing computer aided design and solid free form 
fabrication into the molding process. 
 
 Our preliminary data show that adult human nasal chondrocytes represent a 
possible cell source for clinical applications of tissue engineered neo-cartilage with 
several very attractive features. Using injection molding technology and calcium-
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alginate, adult human nasal septal chondrocytes expanded through 1 passage enable 
the production of engineered constructs as large as 8 grams from an initial septal 
biopsy as small as 100 milligrams. The biochemical data on matrix deposition 
presented here show similar initial results to an earlier study by Rotter et al32 using 
human nasal septal chondrocytes seeded onto PGA/PLA discs, cultured briefly in 
vitro, and then in-vivo in athymic mice to twelve weeks. In that study, in contrast to 
the present one, the matrix deposition peaked quickly and then tended to level off or 
decline by 4 weeks. The continual deposition of matrix seen in the current study may 
indicate a stronger chondrogenic potential for nasal septal chondrocytes when grown 
in alginate compared to PGA/PLA. The high variability in DNA content may 
represent technical imprecision, but also may represent a differing tendency for 
proliferation or matrix deposition depending on the age of the donor cartilage. This 
possibility will be examined in future studies. 
 
 There are several outstanding questions from the current study that could 
prove important. With this system matrix deposition was seen to continue for the 
entire length of the study, close to six months. At this time it remains unclear how 
long tissue development would continue with this system, or if the current 
technologies would produce similar results in an in vitro culture system. Future work 
will look to improve the quality of shape duplication by the application of computer 
aided design and solid free form fabrication in the mold making process, and possible 
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modifications of alginate to allow it to serve as a growth factor deliver system. These 
ideas will be explained in detail in the following chapters. 
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Figure 1 
Schematic of injection molding process. Human nasal septal cartilage was digested in 
type II collagenase, grown in monolayer culture, passaged, mixed with calcium 
alginate, injected into a negative mold, unmolded, and implanted subcutaneously into 
the dorsum of an athymic mouse. 
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Figure 2 
Nasal septal biopsy before digestion (A), formed construct immediately after un-
molding (B), and engineered tissue after 12 weeks of in vivo growth (C). 
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Figure 3 
Safranin-O staining of engineered constructs at (A) 2 weeks, (B) 4 weeks, (C) 6 
weeks, and (D) 12 weeks after subcutaneous implantation.  
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Figure 4 
Hydroxyproline content measured after removal from subcutaneous implantation. 
Each data point represents n = 6 ± standard deviation. The correlation coefficient and 
p values indicate levels of significance of change in hydroxyproline with time. 
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Figure 5 
Glycosaminoglycan content measured after removal from subcutaneous implantation. 
Each data point represents n = 6 ± standard deviation. The correlation coefficient and 
p values indicate levels of significance of change in Glycosaminoglycan with time. 
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Figure 6 
DNA content measured after removal from subcutaneous implantation. Each data 
point represents n = 6 ± standard deviation. The correlation coefficient and p values 
indicate levels of significance of change in DNA with time. 
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Figure 7 
Compressive equilibrium modulus of molded constructs after removal from 
subcutaneous implantation. Each data point represents n = 6 ± standard deviation. The 
correlation coefficient and p values indicate levels of significance of change in 
compressive equilibrium modulus with time. 
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Figure 8 
Collagen content measured after removal from subcutaneous implantation. Dashed 
lines represent the predicted total collagen range calculated with hydroxyproline 
content taken to range from 12.3%-14.4% of the total collagen content. The solid line 
is type II collagen as measure by ELISA. Each data point represents n = 6 ± standard 
deviation. 
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Abstract 
 Objectives/Hypothesis. The goal of the current study was to utilize computer 
aided design and injection molding technologies to tissue engineer precisely shaped 
cartilage in the shape of butterfly tympanic membrane patches out of chondrocyte 
seeded calcium alginate gels.  
 
 Methods. Molds were designed on Solid works 2000 and built out of 
acrylonitrile butadiene styrene (ABS) utilizing fused deposition modeling (FDM). 
Tympanic membrane patches were fabricated using bovine articular chondrocytes 
seeded at 50 x 106 cells/ml in 2% calcium alginate gels. Molded patches were 
cultured in vitro for up to ten weeks, and assessed biochemically, morphologically, 
and histologically.    
 
 Results. Un-molded patches demonstrated outstanding dimensional fidelity 
with a volumetric precision of at least 3µls, and maintained their shape well for up to 
ten weeks of in vitro culture. Glycosaminoglycan and collagen content increased 
steadily over ten weeks in culture, demonstrating continual deposition of new 
extracellular matrix, consistent with new tissue development.     
 
 Conclusions.   The use of computer aided design and injection molding 
technologies allows for the fabrication of very small, precisely shaped chondrocyte-
seeded calcium alginate structures that faithfully maintain their shape during in vitro 
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culture. In vitro fabrication of tympanic membrane patches with a precisely controlled 
geometry may have the potential to provide a minimally invasive alternative to 
traditional methods for the repair of chronic tympanic membrane perforations. 
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Introduction 
 Over two million tympanostomy tubes are inserted annually in the United 
States, making this the most commonly performed of all surgical procedures1. In up 
to ten percent of cases the patient treated with tympanostomy tubes is left with a 
permanent perforation of the tympanic membrane that requires surgical repair2. 
Because of the enormous number of chronic tympanic membrane perforations that 
need to be treated surgically every year, any new treatment that can simplify the 
repair process without sacrificing outcome quality has significant potential benefits. 
Current surgical reparative techniques require harvesting autologous tissue such as 
temporalis fascia or tragal cartilage to close the defect3. The tragal cartilage, or so 
called cartilage butterfly technique, is a relatively new and very promising transcanal 
inlay procedure that, in many cases, has several distinct advantages over more 
traditional tympanoplasty. It demonstrates excellent results in closing the tympanic 
membrane, and effectively restores and maintains normal audiometric function 
without requiring removal of contiguous myringosclerosis plaques or the creation a 
tympanomeatal flap. For these reasons the cartilage butterfly approach can sometimes 
be performed with mask anesthesia in an outpatient surgery setting4.   
   
 Any highly effective treatment for chronic tympanic membrane perforations 
that could be performed reliably in an outpatient setting without the need for general 
anesthesia would provide an easier experience for patients and their families as well 
as potentially greatly reduce the cost of treatment. The cartilage butterfly approach to 
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tympanic membrane repair is a positive step in this direction, but is often limited by 
the invasiveness of harvesting the tragal cartilage as well as by the time and 
discomfort associated with shaping the harvested cartilage to make the appropriate 
geometry needed for repair.  
  
 Tissue engineering is an area of science in which investigators strive to repair 
or regenerate damaged or lost tissue. There is currently active investigation into the 
tissue engineering of a wide variety of specific tissues5. The common theme unifying 
the tissue engineering approach is the principle that a wide variety of cell types can be 
coaxed into synthesizing new tissue if they are seeded onto an appropriate three 
dimensional scaffold in an appropriate growth environment6.  Seeding chondrocytes 
into a biocompatible and bioabsorpable three dimensional scaffold, such as alginate 
localizes the cells to a desired area and geometry allowing for new extracellular 
matrix (ECM) production in a desired location and shape7,8. Cartilage regeneration 
occurs as the chondrocytes are cultured in-vitro, seeded in a three dimensional 
polymer scaffold of the desired shape. As new tissue develops the polymer scaffold is 
reabsorbed so that ultimately new tissue is formed in the shape of the polymer in 
which the cells were seeded. 
  
 For many tissue engineering purposes it is desirable to precisely control the 
geometry of the newly generated tissue. The most common approach researchers have 
taken to controlling shape is to press fibrous scaffolds such as polyglycolic acid 
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(PGA) or polylglycolic-co-lactic acid (PLGA) into a rigid mold and then seed this 
scaffold with a cell solution 9. This process works to some degree, but has inherent 
difficulties. It is technically challenging in this process to control the homogeneity of 
both polymer and cell distribution, complicating the ability to reliably produce 
consistent results. Additionally, cell-seeding efficiency tends to be low10 and shape 
generation somewhat operator dependent. To our knowledge there are no reports to 
date of this approach being used to successfully fabricate very small precisely shaped 
constructs. Previously published work demonstrated calcium alginate production of 
complex geometries utilizing injection molding11. In this work silicon maxillofacial 
implants were used as positives to generate negative molds from a commercially 
available silastic mold making kit. Calcium alginate was then injected into the molds 
to duplicate the silicon shapes. The results demonstrated the utility of the process, but 
also some inherent limitations. Complete filling of the molds was difficult, and the 
process was not capable of reliably generating very small constructs. Additionally, in 
order to create an injection mold one needed a structure serving as a positive that 
already possessed the desired geometry.  This study addresses these limitations by 
incorporating computer aided design (CAD), which eliminates the need for the 
existing positive, and solid free form fabrication which allows for the fabrication of 
sophisticated mold elements.  
 
We propose that the cartilage butterfly approach to tympanic membrane repair 
would benefit from using a tissue engineered autologous cartilage patch in lieu of 
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intra-operatively harvesting and shaping tragal cartilage. Our tissue engineering 
approach strives to generate new cartilage in the shape of a butterfly tympanic 
membrane patch from a very small number of autologous chondrocytes harvested 
from an unobtrusive retro-auricular or tragal site using local anesthesia.  
  
 In the current study we have sought to demonstrate the feasibility of a tissue 
engineering approach for tympanic membrane perforation repair by fabricating 
cartilage butterfly patches of three different sizes using bovine articular chondrocytes 
seeded in shaped calcium-alginate constructs. Toward this end we evaluated the 
ability of CAD and injection molding technologies for their ability to reliably 
reproduce very small and precisely shaped cell-seeded calcium alginate gels that 
maintain a complex geometry  during in vitro culture, as well as the chondrogenic 
potential of these gels in a standard in vitro culture system.  
 
To insure precise geometry and dimensional tolerances for the patches we 
utilized an injection molding technology specially adapted for an alginate/cell mixture 
with a mold designed by computer-aided design (CAD), and fabricated by fused 
deposition modeling (FDM), a kind of solid freeform fabrication.
Methods and Materials 
 Chondrocyte Isolation. Bovine articular chondrocytes were isolated from the 
glenohumoral joint of freshly slaughtered calfs. Cartilage slices were excised from the 
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joint and washed thoroughly two times in phosphate buffered saline (PBS) (Sigma-
Aldrich, Irvine, CA, USA) supplemented with antibiotic/antimycotic (10,000 U/ml 
penicllin G sodium, 10,000 µg/ml streptomycin sulfate, and 25 µg/ml amphotericin 
B) (Gibco, Grand Island NY). Cartilage slices were then enzymatically digested in 
0.3% collagenase type II (Worthington Biochemical Corp, Freehold, N.J. USA.) in 
Hamms F-12 media (Sigma-Aldrich, Irvine CA) at 37° for 12-16 hours12. The 
resultant digest was filtered through a sterile 180 um polypropylene filter (Millipore, 
Bedford, MA) to separate the chondrocytes from any undigested cartilage. The 
filtered collagenase solution was centrifuged at 7000 rpm, and the pelleted cells were 
washed thoroughly twice in antibiotic/antimycotic supplemented PBS. Isolated 
chondrocytes were re-suspended in Hamm’s F-12 media supplemented with 
antibiotic/antimycotic, and counted on a hemocytometer. Cell viability was assessed 
by trypan blue dye exclusion assay (Sigma-Aldrich, Irvine, CA). All cells used in 
construct fabrication were taken from digests that demonstrated better than 90% cell 
viability. 
 
Mold Design and fabrication . An injection mold for fabricating tissue 
engineered tympanic membrane patches was designed using SolidWorks 2000 
(Computer-Aided Products, Peabody, MA) and fabricated out of acrylonitrile 
butadiene styrene (ABS) using fused deposition modeling (FDM), on a Stratysys 
Inc.’s Prodigy (Stratysys Inc, Eden Prairie, MN). The mold was designed with a part-
line along an axis of symmetry to avoid undercuts, and had two alignment pins at one 
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end to ensure proper marriage of the two halves (Fig 1). The mold was designed with 
an injection port at one end and off-gassing slits at the far end of each individual 
patch to insure proper filling of the mold cavity (Fig 1). The injected mold makes two 
copies each of three different sizes of “butterfly” tympanic membrane patches. Same 
size patches are molded in parallel and the different sizes in series (Fig 1). The 
butterfly shape patch was modeled after the target shape of surgically carved tragal 
cartilage, (two circular flanges flanking a central connector). In the injected mold the 
patches sit on top of two inserts that can be pushed out from the back to facilitate 
removal from the mold (Fig 1). All three patches are 2 mm long across their major 
axis and have flanges with outer diameters ranging from 2 mm-3 mm. The thickness 
of the flanges is roughly 0.40 mm.  
 
Construct Fabrication and Handling . Methods for generating chondrocyte-
seeded alginate patches were based on previous studies documenting generation of 
cartilage by injection molding11. Chondrocytes isolated from enzymatic digestion of 
bovine articular cartilage were suspended in filter sterilized 2% low viscosity alginate 
(Pronvoa, Norway) in PBS at a seeding density of 50 x 106 cells/ml. Immediately 
prior to injection into the mold the alginate/cell suspension was mixed thoroughly, 
using a sterile stopcock, with autoclave sterilized CaSO4 in PBS (0.25g/ml). The 
alginate/chondrocyte/ CaSO4  mixture was injected into the mold using a 3 ml syringe 
with an 18.5 gauge needle.  Over time the Ca++ in the alginate/chondrocyte/CaSO4 
solution continually cross-links individual alginate strands, leading to a progressively 
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stiffer and stiffer gel. The injected molds were allowed to stand for one hour, after 
which fully formed solid gelled patches were removed. (Fig. 2) The individual 
patches were cultured in vitro for up to 10 weeks in Hamm’s F-12 media 
supplemented with antibiotic/antimycotic), 10% heat inactivated fetal bovine serum 
(FBS), and ascorbate (50 µg/ml). (Fig 4) All patches were cultured in 6 well culture 
dishes, with different size patches isolated from each other. A maximum of six 
patches were cultured in any individual well. Cultured patches were covered with 8 
mls of culture medium which was changed every second day.  
 
Histological Evaluation of Constructs . At 0 and 10 weeks samples were 
removed from culture and frozen for histological and biochemical evaluation.  
Specimens for histology were fixed in 10% unbuffered formalin supplemented to be 
0.1M in CaCl2 for at least 24 hours and then embedded in paraffin, sectioned by 
microtome, and stained with Safranin-O.  
 
Biochemical Evaluation of Constructs . In parallel with histological studies, 
samples were removed from culture at 2, 4, 6, and 10 weeks for biochemical 
evaluation. Cell number in the constructs was evaluated by quantifying the amount of 
DNA. Extracellular matrix accumulation in the constructs was evaluated by 
quantifying the amount of sulfated glycosaminoglycans (GAGs) as a marker of 
proteoglycans, and hydroxyproline as a marker of collagen content. All biochemical 
analysis used standard methods that have been described elsewhere in detail. Briefly, 
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all samples were digested in 1 ml of a papain digest buffer (0.1M sodium phosphate, 
10 mmol sodium EDTA (BDH), 10 mmol cysteine hydrochloride (Sigma), and 3.8 
U/ml papain (Sigma) at 60° for 24 hours. DNA content of samples was measured by 
quantitating the amount of fluorescence (358/458 nm) due to bound Hoechst 33258 
dye. Measured fluorescence from the samples was compared to a standard curve 
created with calf thymus DNA13. Sulfated GAG content was measured using 1,9- 
dimethylmethylene blue dye at pH 1.5, and quantitating the absorbances at 595 nm, 
using C-6-S from shark cartilage (Sigma) as a standard14.  Hydroxyproline content 
was measured by acid hydrolysis of samples of papain digests, addition of 
Chloramine T and pdimethylamino-benzaldehyde, and quantitating the absorbance at 
560 nm15. 
 
Mass Evaluation of Constructs . In order to determine if the mold was 
faithfully reproducing the shape of the patches, we compared the masses of the three 
different size patches immediately after un-molding to the expected mass for each 
size patch. Each measured mass used for comparison was the average mass of thirty 
individually weighed patches. Expected masses were determined based upon the 
designed patch volumes and a measured density of the cross-linked alginate gel. Each 
sample was weighed to 0.0001g using a microbalance (Ohaus, Pine Brook, NJ) and 
the weights were recorded. 
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Statistical Analysis. Mean differences in GAG, hydroxyproline, and DNA 
content at 2, 4, 6, and 10 weeks were analyzed by a one factor ANOVA with tukey 
post-hoc multiple comparisons. 
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                                                       Results 
 The ABS mold faithfully reproduces the computer generated design, yielding 
tympanic membrane patches which can be separated and removed from the mold. The 
average masses of the three different size patches immediately after un-molding were 
30.2 ± 3.1 mg, 21.6 ± 2.2 mg, and 10.6 ± 2.2 mg (90%, 89%, and 88% of expected 
values) (Fig 3). For each size patch this represents a volume discrepancy of 3 µl or 
less, demonstrating an excellent ability to accurately duplicate small shapes. The 
gross morphology of the patches was maintained through 10 weeks of in-vitro 
culture, and over time the patches gradually became more opaque, grossly consistent 
with developing extracellular matrix. This is most apparent between 6 and 10 weeks 
(Fig 4).  
 
Immediately after un-molding the samples show good shape fidelity, and air 
bubbles generated from mixing alginate with CaSO4 can be seen (Fig 5). At 10 weeks 
samples still show excellent shape retention, with Safranin-O staining throughout, 
indicating relatively uniform deposition of proteoglycans, an important component of 
the cartilage extracellular matrix. The periphery of the samples contained a thin (10-
20 µm) layer that did not stain with Safranin-O.  
 
GAG and hydroxyproline content increased significantly between each 
measured time point (p<0.002). DNA content showed no statistically measurable 
difference over time. At 2, 4, 6, and 10  weeks GAG content was 1.1 ± 0.56 µg/mg , 
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2.02 ± 0.91 µg/mg, 3.83 ± 1.60 µg/mg, and 9.33 ± 2.3µg/mg. (Fig. 6) These values 
are roughly 2%, 3%, 6% and 13% respectively of native values. At 2, 4, 6, and 10 
weeks hydroxyproline content was 0.07 ± 0.03 µg/mg, 0.14 ± 0.05 µg/mg, 0.67 ± 
0.27µg/mg. and 0.94 ± 0.27 µg/mg. (Fig. 8) These values are approximately 1%, 2%, 
10%, and 15% respectively of native values measured as an internal control. 
Increasing GAG and hydroxyproline content indicate that the chondrocytes were alive 
and metabolically active. DNA content over time remained consistent with the DNA 
content initially loaded, indicating that the chondrocytes did not proliferate in the 
course of this culture. (Fig. 6)  
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Discussion 
The goal of the present study was to assess the potential of CAD and injection 
molding technologies to generate chondrocyte seeded calcium alginate gels in the 
shape of cartilage butterfly tympanic membrane patches, and to then assess the 
chondrogenic potential of those constructs to determine their potential suitability for 
therapeutic application in the treatment of chronic tympanic membrane perforations.  
 
Alginate, an anionic copolymer of manuronic and guluronic acids, has been 
used for many years for in vitro culture systems, and in more recent years has gained 
interest as a scaffold for tissue engineering16. Because of the relatively low aqueous 
solubility of the alginate cross-linking solution used in this study, CaSO4 (0.209 
g/ml), the amount of the cross-linking agent, free Ca++, available at equilibrium is 
scant enough that cross-linking of alginate occurs slowly enough that the 
alginate/cell/ CaSO  mixture 4 can be injected into a mold as a liquid, but in a 
reasonably short time forms a stiff enough gel to be un-molded as a solid.   
 
The most commonly used scaffold in tissue engineering has been polyglycolic 
acid (PGA), which has demonstrated the ability to facilitate new tissue development, 
but has provoked a severe inflammatory reaction when implanted in 
immunocompetent animals17. An appealing element of alginate as a tissue 
engineering scaffold is that it allows for new tissue development  in a three 
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dimensional matrix while, unlike PGA, seems  to provoke little or no immune 
response in immunocompetent hosts17.  
 
The tympanic membrane patches fabricated in this study demonstrated good 
dimensional fidelity, with volumetric precision to within 3 µl of design specifications 
for all size patches, indicating excellent potential for making very small precisely 
shaped cell-seeded constructs. Increasing GAG and hydroxyproline content indicate 
that the chondrocytes were alive and metabolically active, continually producing new 
extracellular matrix. The DNA data indicate that the chondrocytes did not proliferate, 
which is consistent with metabolic energy being conserved for extracellular matrix 
development, as was desired. These biochemical data are reasonably consistent with 
reports on similar in vitro cartilage development, and are consistent with the 
development of new cartilage18.  Chondrogenic potential of the cultured constructs 
was further demonstrated by progressive staining with Safranin-O during in vitro 
culture. Good cross-sectional morphology was difficult to see on histology due to the 
technical challenge in preparing the constructs. Upon removal from the mold the 
alginate gel is still quite soft and subject to deformation during the imbedding 
process, particularly at the very thin outer flanges.    
 
The increasing trend in matrix components shows that tissue development was 
continuing with time in culture. Also, while ECM development, which strongly 
correlates with the developing tissue’s mechanical properties, is for some cartilage 
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tissue engineering applications perhaps the most crucial indication of tissue utility, 
that is not necessarily the case here. Using a cartilage tympanic membrane patch is 
fundamentally different from trying to create load bearing, structural cartilage. For 
this application, it is unclear, as of now, how crucial the mechanical properties of the 
new tissue will be, but by ten weeks of in vitro culture the patches had solidified 
sufficiently that they could be picked up and handled with forceps.   
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Conclusion 
 We have demonstrated the ability to tissue engineer cartilage implants with 
the precise shape necessary for repair of non-healing perforated tympanic membranes 
caused by long term use of tympanostomy tubes. Determination of how well these 
constructs work for the clinical repair of non-healing tympanic membrane 
perforations will require an in vivo study using an animal model of non-healing 
tympanic membrane perforations. In future studies we will also compare tissue 
engineered cartilage patches with patches made from other tissue engineered tissues. 
The clinical use of a tissue engineered patch for repair of tympanic membranes has 
the potential to allow repair of small tympanic membrane perforations to be 
accomplished at an office visit, with no need for general anesthesia in select cases. 
Moving the routine repair of non-healing tympanic membrane perforations due to 
long term tympanostomy tube use from the operating room to the office has the 
potential to greatly reduce the time and stress of treatment for patients and 
additionally to greatly reduce the cost of providing treatment. To accomplish the 
long-term goal of this work, though, much work needs to be done in the animal model 
in order to optimize the formulation and design of the implants. In addition, future 
work utilizing alternative cell types may facilitate an “off-the-shelf”, one-step 
tympanic membrane patch. 
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Figure 1.  
CAD rendering of the mold generated in SolidWorks 2000 Unexploded (A),  and 
Exploded (B). 
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Figure 2.  
ABS mold filled with alginate seeded with 50 x 106 chondrocytes/ml immediately 
before un-molding (A), and molded patches immediately prior to culture (B). 
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Figure 3.  
Calculated and expected masses of small medium, and large tympanic membrane 
patches immediately after un-molding. 
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Figure 4.  
Gross morphology at 2 weeks (A), 4 weeks (B), 6 weeks (C), and 10 weeks (D) in 
culture. 
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Figure 5.  
Safranin O staining of a small tympanic membrane patch to detect cartilage 
proteoglycans immediately after un-molding (A at 40x magnification and C at 200x 
magnification), and a large tympanic membrane patch after 10 weeks in culture (B at 
40x magnification and D at 200x magnification). Bar = 500 µm. 
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Figure 6.  
Glycosaminoglycan (GAG) content (A), hydroxyproline content (B), and DNA 
content (C) of tympanic membrane patches at times in culture up to 10 weeks. All 
data are represented as mean ± SD for n = 24 samples.  
 
 
 
 
 
 
 
 
 
 
 75
CHAPTER 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PEPTIDE MODIFIED ALGINATE HYDROGELS: A POTENTIAL 
VEHICLE FOR THE CONTROLLED RELEASE OF TGF-β1 IN A 
TISSUE ENGINEERING SCAFFOLD 
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Abstract 
 
 
 Objectives/Hypothesis. The goal of the current study was twofold: first, to 
evaluate the efficiency of carbodiimide chemistry for adding a novel growth factor 
binding peptide to sodium alginate; second, to compare the TGF-β1 release 
characteristics from peptide-modified alginate and control alginate. 
 
 Methods. A novel growth factor binding peptide was covalently bonded to 
sodium alginate using standard carbodiimide chemistry to form amide linkages 
between the N-terminal region of the peptide and the free carboxylate moieties on the 
alginate backbone. The efficiency of the reaction was determined using the BCA 
Protein Assay. Control and peptide-modified alginate were loaded with 30 ng/ml 
TGF-β1 and stored in PBS at 37ºC. TGF –β1 release from experimental and control 
constructs was quantified by ELISA over 16 days  
 
 Results. Carbodiimide addition of the novel growth factor binding peptide 
proceeded at 60% efficiency, consistent with previously published reports on 
carbodiimide addition of peptides to sodium alginate. The peptide-modified alginate 
displayed different release characteristics than control alginate, delaying a burst 
release of growth factor by approximately three days.  
 
 Conclusions. Carbodiimide chemistry can reliably add a variety of growth 
factors to calcium alginate in a predictable manner. Peptide modification of alginate 
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resulted in altered release characteristics for TGF-β1. This may have been due to 
specific binding to the peptide or alterations in the properties of the alginate construct. 
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Introduction 
 
Osteoarthritis effects as many as twenty-one million people in the United 
States, and is responsible for over 50% of all hip replacements. This alone results in 
annual medical costs exceeding fifteen billion dollars1. There are over one million 
surgical procedures annually in the United States that involve the replacement of bone 
or cartilage2. Given this enormous societal cost and the debilitating nature of severe 
joint pain, medical science has striven for decades to find ways to encourage cartilage 
regeneration and repair. This work is difficult because of the inherently poor ability of 
cartilage for self repair. Because cartilage is an avascular tissue, partial thickness 
injuries that do not extend down to the level of the subchondral bone are incapable of 
spontaneous healing. Without a vascular supply, cells, growth factors and cytokines 
cannot be recruited to the site of injury to aid in repair as happens in most other 
tissues. 
 
 For severely damaged articular cartilage with debilitating joint pain the only 
currently available treatment is prosthetic joint replacement. While this does provide 
symptomatic relief, prosthetic joints have a limited life span and cannot fully replicate 
cartilage’s resistance to compression and ability to evenly distribute load3. Thus, the 
ability to repair native cartilage, or replace damaged or diseased cartilage with an 
engineered replacement would be of tremendous benefit in the treatment of joint 
disease. The tissue engineering approach to repairing cartilage acknowledges that 
tissue repair will require a space filling matrix, cells, and appropriate biologics. 
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Alginate, a copolymer of mannuronic and guluronic acids, is a hydrogel that has been 
used extensively for three dimensional chondrocyte culture, and more recently as a 
tissue engineering scaffold, effectively serving as synthetic extracellular matrix 
(ECM)4-7. A primary goal of tissue engineering is to be able to take a very small 
amount of tissue, and transform it into a much greater amount of tissue that can be 
used for therapeutic purposes. This is accomplished by liberation and expansion of 
the cells from donor tissue, followed by seeding into a polymer scaffold. The idea in 
using a scaffold is to provide an environment that essentially replaces the function of 
the ECM. Namely, it allows cells to organize in a three dimensional structure, 
provides mechanical stability, provides for localization of cells, and provides a 
hydrated space for the diffusion of nutrients and cellular metabolites8-9. 
 
 Alginate has been used for decades for the three dimensional culture of 
chondrocytes, where it has been shown to maintain the chondrocyte phenotype, which 
is lost in standard monolayer culture10-13. Alginate has been previously shown to have 
utility as a tissue engineering scaffold for fabricating chondrocyte seeded structures 
with complex geometries that have outstanding structural fidelity in in vitro culture14. 
Alginate is also intriguing as a tissue engineering scaffold for its chemical properties. 
As a hydrogel, it is subject to solution chemistry, making it easier to modify than 
rigid polymers. As a copolymer of two acids it has abundant free carboxylic acid 
moieties that are highly reactive and naturally subject to condensation reactions. This 
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makes it possible to conceive numerous peptide modifications of alginate to regulate 
such important functions as cell adhesion and growth factor delivery. 
 
 The necessity of growth factors and other biologically active molecules for 
orchestrating tissue development in tissue engineering applications has long been 
accepted. Numerous growth factors have been investigated for the engineering of 
articular cartilage, including the TGF-β superfamily, IGFs, FGFs, PDGF, EGFs, 
VEGF, and numerous others15-24. From this increasingly dizzying array, TGF-β1 
stands out for a number of reasons. TGF-β is the most studied growth factor for 
chondrogenesis, and TGF-β1 is the most abundant naturally occurring isoform in 
articular cartilage25.  TGF-β1 has consistently been shown to be a potent stimulatory 
of chondrogenic differentiation, and extracellular matrix production26-31. How best to 
deliver TGF-β to chondrocytes in tissue engineered constructs is not known. While in 
principal this can be done in a number of ways, the key element, if it is to be 
effective, is that the growth factor must be supplied in a controlled manner. 
 
 One of the major carriers of TGF-β endogenously is the homotetrameric 
glycoprotein, α2-Macroglobulin (α M). α2 2M functions as broad spectrum proteinase 
inhibitor in plasma and other extracellular spaces. It functions in this manner by 
presenting multiple peptide bonds in its so called “bait” region to proteinases. When 
these peptide bonds are cleaved by an attacking proteinase it causes a conformational 
change in the entire α2M protein, trapping the attacking proteinase32-33. Recently a 
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linear 16 amino acid sequence has been isolated from the bait region of α2M that 
appears able to bind a wide variety of growth factors, including TGF-β134. 
Modification of alginate by biochemical addition of this peptide could potentially 
allow for the controlled release of TGF-β1 from calcium alginate constructs. In the 
current study we will attempt to modify alginate by covalent addition of this TFG-β 
binding peptide, and characterize the subsequent release of TGF-β1 from this 
modified alginate compared to control alginate. 
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Methods and Materials 
 
 
Custom Peptide Synthesis . Medium viscosity alginate was purchased from 
FMC Biopolymer (Drammen Norway), and the modified TGF-β binding peptide, 
glycine, glycine, glycine, glycine, tryptophan, aspartic acid, leucine, valine, valine, 
valine, asparagine, serine, alanine, glycine, valine, alanine, glutamic acid, valine, 
glycine, valine, tyrosine, tyrosine, abbreviated as, 
GGGGWDLVVVNSAGVAEVGVYY, was purchased as a custom synthesis order 
from New England Peptide Inc. (Gardner, MA). The N-terminal GGGG sequence 
was added to the known TGF-β binding peptide as a known linking sequence used 
with alginate, and the C-Terminal YY sequence was added to aid in peptide detection 
by the BCA Protein Assay Kit. All other reagents were purchased through Sigma 
Aldrich in Irvine, CA. 
 
Fabrication of Peptide Modified Alginate . The TGF-β binding peptide 
sequence, GGGGWDLVVVNSAGVAEVGVYY, was covalently bonded to alginate 
utilizing aqueous carbodiimide chemistry as has been previously described for 
fabricating alginate gels modified with other peptide sequences33. 
Briefly, in what is essentially a protected nucleophilic acyl substitution reaction, the 
carbodiimide approach to peptide bonding was used to form amide linkages between 
the N-terminus of the binding peptide and the carboxylate moieties on the 
mannuronic acid and guluronic acid residues of the alginate backbone. Medium 
viscosity alginate (FMC Biopolymer, Drammen, Norway) was suspended in 100 mM 
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MES (2-N-Morpholino ethane sulfonic acid) buffer with 300 mM NaCl at pH 6.5 to 
make a 1% alginate solution. EDAC (l-ethyl-dimethylaminopropyl carbodiimide) and 
Sulfo-NHS ((N-hydroxy-sulfosuccinimide) were added to the alginate solution at 
molar ratios of 5% and 2.5% of the guluronate content of the alginate respectively. 
Finally, the TGF-β binding peptide was added as 49.2 mg in 1 mg/ml MES buffer. 
The reaction was allowed to proceed at room temperature for approximately 20 hours 
and then the solution was transferred to 3500 MWCO dialysis tubing in a 4 liter 
solution of ddH2O and NaCl. The dialysis bath was changed every 8 hours for three 
days, with the NaCl concentration being progressively lowered with each change. The 
peptide was dialyzed against pure water for the last 24 hours. The final contents of the 
dialysis tube was transferred to 50 ml conical tubes, frozen at -86ºC and lyophilized 
for approximately 48 hours, until dry. Unmodified alginate to be used as a control 
was processed exactly in parallel with the one exception that no peptide was added. 
The lyophilized alginates were resuspended as a 2% solution in PBS. 
 
Reaction Efficiency .  The efficiency of covalent addition of peptide addition 
to alginate was assessed using the BCA Protein Assay kit, (Pierce, Rockford, Il), 
according to the manufacturers instructions. Briefly, 25 μl of the of the peptide 
modified alginate in a 2% solution of PBS was combined with 200 μl of the BCA 
working reagent in a 96 well microplate. The plate was covered and mixed on a plate 
shaker for 30 seconds, and then incubated at 37ºC for 30 minutes.  After incubation 
the plate was cooled to room temperature and absorbance was measured at 562 nm on 
an HTS 7000+ spectrophotometer (PE Wellesley, MA). Peptide content of the 
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modified alginate was determined by linear interpolation using 2% control alginate 
with varying concentrations of peptide directly added as a standard. All samples and 
standards were analyzed in triplicate, and the results averaged. 
 
TGF-β1 Loaded Alginate Preparation . TGF-β1 (PeproTech) stock solution 
(50 μg/ml) was diluted 10:1, and 12 μl of the diluted stock solutions was combined 
with a separate 2 ml aliquot of a 2% solution of low viscosity alginate (FMC 
Biopolymer, Drammen, Norway) in PBS, making the concentration of TGF-β1 
loaded alginate, 30 ng/ml. The alginate was then combined with a sterile solution of 
CaSO4 (0.25g/ml) by thorough mixing through a sterile stopcock (David Scott, MA). 
The CaSO4 solution was used at 0.04 milliliters per milliliter of alginate. The 
alginate/TGF-β1/CaSO4 solution was then injected between two sterile glass 
electrophoresis plates with a 1 mm spacer, and allowed to gel for 30 minutes. 
Uniform alginate discs were cut from the gelled alginate with a 6mm dermal biopsy 
punch. Discs were collected and placed in an 8 well culture dish at 1.0 mg per well, 
covered with 9 mls of sterile PBS per well, sealed, and stored at 37ºC. Control 
alginate was prepared in parallel, without the addition of the TGF-β1 binding peptide.    
 
In Vitro Release Studies . The in vitro release of TGF-β1 was analyzed for 
two conditions: peptide modified and control alginate at an initial loading 
concentration of 30 ng/ml. At each time point (days 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12 and 
16), the total fluid was collected for analysis, and replaced with fresh PBS. 
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Cumulative release of TGF-β1 over 16 days was determined by ELISA. Each 
condition was run in duplicate and the results averaged. 
 
 
TGF-β1 Elisa . TGF-β1 content was determined using the TGF-β1 Emax 
ImmunoAssay System (Promega, Maddison, WI), according to the manufacturer’s 
instructions. Briefly, 10 μl of the provided TGF-β1 capture antibody was combined 
with 10 mls of carbonate coating buffer (025M NaHCO , 0.025 NaCO3 3), mixed 
thoroughly, and added at 100 μl per well to a 96 well polystyrene ELISA plate 
(Corning Life Sciences, Lowell, MA). This plate was sealed and incubated statically 
at 4ºC overnight. The plate was allowed to return to room temperature, emptied, and 
270 μl of the supplied TGF-β1 blocking buffer was added to each well, statically 
incubated at 37ºC for 35 minutes, then washed once in prepared TBST wash buffer 
(20mM Tris-HCl (pH 7.6), 150mM NaCl, 0.05% Tween 20). Serial dilutions of the 
provided TGF-β1 standard was added at 100 μl per well to make a standard curve 
with a range from 0-1000 pg/ml. Samples were added at 100 μl per well, and the 
plates were incubated for 90 minutes on a plate shaker at room temperature. The 
provided anti-TGF-β1 antibody, diluted 1000:1 in the sample buffer, was added at 
100μl per well, the plate was incubated on plate shaker at room temperature for two 
hours, then washed 5 times with TBST wash buffer. TGF-β1 HRP Conjugate diluted 
1:100 was added at 100μl/well, incubated on a plate shaker for 2 hours at room 
temperature, and washed 5 times with TBST wash buffer. The provided TMB One 
Solution was added at 100 μl per well, and statically incubated at room temperature 
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for 15 minutes. The reaction was stopped by adding 1N hydrochloric acid at 100 μl 
per well. The plate was read on an HTS 7000+ spectrophotometer (Perkin-Elmer, 
Wellesley, MA) plate reader at 450 nm, and TGF-β1 was calculated by linear 
interpolation with the provided TGF-β1 standard. All samples and standards were 
analyzed in duplicate and the results averaged. 
 
 
Statistical Analysis . The results are displayed as the mean ± a standard 
deviation. Statistical difference between means at each time point was evaluated by 
an unpaired two-tailed t-test. The threshold for statistical significance was taken to be 
p < 0.05.  
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Results 
 
 
Carbodiimide Efficiency.  The efficiency of covalent peptide addition to 
alginate was determined by the BCA Protein Assay Kit and linear interpolation of 
prepared standards of alginate with known amounts of added peptide. The calculated 
efficiency of the reaction was 60%, which is consistent with prior report of the 
efficiency of the carbodiimide process using alginate and different peptides34. (Figure 
1) This consistency substantiates that hydrogel polymers, such as alginate, that are 
subject to solution chemistry and have abundant free carboxylate moieties that are 
readily and predictably modified by carbodiimide chemistry.  
 
 
TGF-β1in vitro release . The in vitro release of TGF-β1 from peptide-
modified and control alginate was determined using a commercially available TGF-
β1 ELISA kit. The releasate was analyzed at 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 16 days. 
The release of TGF-β1 was affected by incorporation into the peptide-modified 
alginate compared to control alginate. The release profile from the control alginate 
was notable for an early burst, with 42% of the originally loaded TGF-β1 being 
released within the first 12 hours. After this there was a fairly slow, but steady release 
of TGF-β1 of about 2 ng per day. The peptide-modified alginate also demonstrated a 
burst release pattern, but the burst was delayed until day 3. Then again, as with the 
unmodified control alginate, there was a fairly slow and steady release of TGF-β1 
through 16 days.  At the end of 16 days more than 90% of the originally loaded TGF-
β1 from both peptide-modified and control alginate had been released. The difference 
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between the mean release of TGF-β1 from peptide-modified and control alginate was 
only statistically significant (p < 0.001) through 3 days.  
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Discussion 
 
 The goal of the current study was to evaluate the efficiency of carbodiimide 
chemistry to covalently add a newly discovered growth factor binding peptide to 
sodium alginate, and to then characterize the effect that peptide had on the release of 
TGF-β1 from gelled 2% calcium alginate constructs in vitro. 
 
The carbodiimide chemistry achieved an efficiency of 60%, which is remarkably 
consistent with published results for the covalent addition of other peptides to 
alginate. For a polymer scaffold to effectively serve as a temporary synthetic ECM in 
tissue engineering applications it will have to do more than simply provide a rigid 
framework. The ability to easily and reproducibly add a wide variety of peptides to 
alginate in principal should allow it to more precisely fulfill its intended role. 
Alginate gels with attached peptides can begin to take on the regulation of cell 
adhesion and the sequestration and controlled release of growth factors and other 
biologically active molecules.  
 
The peptide-modified alginate showed different release kinetics compared to control 
alginate, principally in delaying a burst release of TGF-β1 from within the first 12 
hours, to between 48 and 72 hours. These results are encouraging, as any ability to 
control the timing and dose of growth factor delivery has enormous potential utility 
for tissue engineering applications. Further work will need to be done to fully 
characterize the system in this study. Control alginate in the next phase will use a 
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“dummy” peptide with no growth factor binding properties to establish that the 
peptide itself does not alter the alginate gel in some way as to alter release kinetics. 
The concentration of TGF-β1 and growth factor binding peptide in future studies will 
be varied in order to evaluate whether or not the reported specific binding of TGF-β1 
is retained after covalent addition to alginate, and if so, what the affinity is. With a 
known affinity, fabricating constructs with appropriate peptide density and TGF-β1 
concentration, it might be possible to control the rate of TGF-β1 release.  
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Figure 1 
 
Characterization of efficiency of carbodiimide peptide linkage to sodium alginate.  
Using standard carbodiimide chemistry 60% of the added peptide was successfully 
incorporated, via peptide linkages, to the alginate backbone.  
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Figure 2 
 
Cumulative release of TGF-β1 from peptide-modified and control alginate. All points 
represent mean ± a standard deviation. Means at all time points were compared by an 
unpaired two-tailed t-test. There was significantly more TGF-β1 released in the 
control alginate (p < 0.001) until day three. 
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Figure 3 
 
Daily release of TGF-β1 from peptide-modified and control alginate. A burst release 
of TGF-β1 can be seen at day 0.5 in the control and at day 3 in the peptide-modified 
alginate. 
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EXPERIMENTAL ENDOLYMPHATIC HYDROPS 
QUANTIFICATION VERSUS HEARING THRESHOLDS IN THE 
ALBINO GUINEA PIG 
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Abstract 
 
  
 Hypothesis. Histological analysis of hydropic and normal guinea pig cochleae 
was undertaken to assess potential correlation between the magnitude of 
endolymphatic hydrops and hearing loss.  We hypothesize that a greater correlation 
than previously reported may be found by looking at well developed hydrops and 
high frequency range hearing. 
 
 Background. Surgically induced endolymphatic hydrops in guinea pigs is the 
most widely used animal model for the study of human Menière’s syndrome 
(endolymphatic hydrops, tinnitus, and progressive sensorineural hearing loss). A 
strong correlation between magnitude of hydrops and severity of hearing loss has 
been reported in the human condition, but not in animal models.   
 
Methods . Nine guinea pigs were operated on to destroy the endolymphatic 
sac of the right ear, with left ears remaining as internal controls. Hearing was assessed 
from 2 kHz to 32 kHz by auditory brain stem response for 6 to 25 weeks post surgery. 
Histological morphometry post sacrifice was used to quantify both turn-specific, and 
weighted, overall hydrops These measures were correlated with hearing loss in each 
animal at all tested frequencies.  
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 Results. A statistically significant relationship between the magnitude of 
hydrops and the severity of hearing loss was found for 2 kHz and 16 kHz. These 
frequencies correlated with both turn-specific hydrops and overall hydrops.  
 
Conclusions. There may be a greater correlation between hydrops and hearing 
loss in guinea pigs with surgically induced hydrops than previously reported. This 
helps to validate the model and highlights the necessity of treatment modalities aimed 
at reducing hydrops. 
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Introduction 
 
Since its introduction by Kimura and Schuknecht in 1965, surgical induction 
of endolymphatic hydrops in the guinea pig has become the standard model for the 
study of Menière’s syndrome.1 This procedure works by blocking the resorption of 
endolymph, and has been readily adopted because it reliably produces both 
histological hydrops and hearing loss. There remain, though, issues regarding the 
model’s utility. At this time it is not clear that the characteristic vestibular symptoms 
of Menière’s syndrome are reproduced in the animal model, or even whether the basic 
physiology of hydrops production is the same as in the human condition. 
Endolymphatic hydrops is a state of excess endolymph in the scala media, so it can 
occur due to insufficient resorption of endolymph, excess production of endolymph, 
or some combination of the two. At this time it is unknown what causes hydrops in 
Menière’s syndrome, so it remains a challenge to understand how best to model the 
human condition. In contrast to the surgical model there are “over production” 
models that have been developed that like the surgical model produce both 
histological hydrops and hearing loss. These include the introduction of cholera toxin 
into the inner ear and various techniques for the induction of inner ear autoimmune 
disease.2-4 Because the mechanism of hydrops production is different in 
overproduction models than in the surgical model it is possible that the 
pathophysiology of hearing loss is also different. At this time it is still unclear 
whether one of these models better replicates the auditory and cochlear pathology 
seen in Menière’s syndrome, so it is important to continue the work of characterizing 
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all animal models as thoroughly as possible. Since surgical induction is still by far the 
most common method for producing experimental endolymphatic hydrops it is 
particularly important to characterize the pathology in this model so that its relevance 
to Menière’s syndrome can be fully appreciated.   
 
While many of the morphological changes in the hydropic cochlea have been 
described, the mechanism for hearing loss in surgically induced hydrops remains 
controversial. It has been noted that distortion of the scala media secondary to 
hydrops is associated with loss of hair cells in the upper two turns of the cochlea in 
both human Menière’s syndrome and surgically induced hydrops.5-6 Since high 
frequency hearing is ultimately affected, though, these same studies imply a poor 
relationship between hair cell loss and degree of hearing loss. In this regard the model 
fits the disease well, but does not explain the phenomenon.  
 
The chief morphological feature of Menière’s syndrome is the distention of 
Reisner’s membrane. While it is widely known that this distention does not occur 
uniformly throughout the cochlea, there remains no good explanation as to why one 
part of Reisner’s membrane might distort differently than another. It has also been 
noted that in both the human condition and the animal model hearing loss follows a 
distinctive pattern: the so called “peak audiogram”, followed finally by a uniform 
hearing loss. That is to say, hearing is lost initially in the low frequencies, then the 
high frequencies, followed lastly by the mid frequencies.7-8 Because of the tonotopic 
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tuning of the cochlea and the fact that neither hearing loss nor Reisner’s membrane 
distension occur uniformly, it is natural to question whether or not there is a 
correlation between the two phenomena. Several studies have looked for a 
quantitative relationship between the degree of hydrops that develops and the severity 
of hearing loss in the animal model, but on the whole have found little or no direct 
correlation.4, 9-10 This is important because in a very thorough study by Fraysse et al. a 
strong correlation between the magnitude of hydrops and hearing loss was established 
in a study of audiograms and archived temporal bones from patients with diagnosed 
Menière’s syndrome.11  
  
Comparisons between previous studies correlating a mathematically 
quantified measure of hydrops and hearing loss in animal models with Fraysse et al.’s 
human findings are difficult for several reasons. Researchers comparing hydrops and 
hearing loss in animals have used the guinea pig, but no studies attempting to 
quantitatively correlate hydrops and hearing loss to date have looked at any hearing 
frequencies beyond 8 kHz. Because guinea pigs can hear up to around 50 kHz, none 
of these studies has looked into the higher ranges for evidence of hearing loss (12). 
Interestingly, in Frassye et al.’s study the only area where there was not a strong 
correlation was in the low (0.25 kHz) frequency range. Hence, the possibility exists 
that animal studies that exclude the high frequency will miss a correlation between 
hearing loss and hydrops. Also, almost without exception previous studies have only 
looked at hydrops very early in its course of development. Fraysse et al. examined 
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temporal bones from patients with long-standing hydrops. For these reasons a 
thorough histological analysis of well developed surgically induced hydrops in the 
guinea pig was undertaken with an effort to fully characterize the pattern and 
magnitude of hydrops via detailed measurements and determine the correlation to 
hearing loss severity across a more representative length of the guinea pig dynamic 
range (2 kHz-32 kKz). In addition, this study is designed to better describe the 
distribution and severity of hydrops across the four turns of the guinea pig cochlea in 
order to document the relative turn specific severity of hydrops and any correlation to 
magnitude and frequency of hearing loss. 
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Methods and Materials 
 
Materials . The experiment was carried out using 9 female albino guinea pigs 
(Duncan-Hartley strain) each initially weighing 250-300 grams obtained from the 
Charles River Breeding Labs (Wilmington, MA). Guinea pigs were anesthetized by 
administration of pentobarbital (16.67mg/kg, IP), xylazine (3.46mg/kg. IM), and 
ketamine (17.28mg/kg, IM). Body temperature was maintained with an electric 
heating pad (Harvard Apparatus, Holliston, MA). All animals were treated in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals, and the 
protocol was approved by the Animal Care Committee at the University of 
Massachusetts Medical School. 
 
Measurement of Hearing Thresholds . All hearing thresholds were obtained 
using Intelligent Hearing Systems’ Auditory Brainstem Response (ABR) system, 
version 3.6x (Intelligent Hearing Systems, Miami, Fl) A custom made sound source 
was used that is described in detail elsewhere (14). Briefly, the sound source was fit 
securely into the external auditory canal of the guinea pig. The sound source 
consisted of a Radio Shack 40-1377 ‘Super Tweeter’ high-frequency dynamic 
speaker, a brass ear bar to direct sound into the ear canal, and a coupler to attach the 
ear bar to the speaker. Subdermal needle electrodes were placed at the midline scalp 
and retroauricularly. Electrical activity was amplified 100,000 times and was filtered 
(0.1-3 kHz) with a bioamplifier. The signal was digitized by an MII signal averaging 
system and an IBM PC clone. Each response was the average of 1024 sweeps 
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presented at a rate of 19.3 Hz and was stored on the PC clone. Threshold of hearing 
was determined to plus or minus 5 dB SPL for frequencies of 2 kHz, 4kHz, 8kHz, 
16kHz, and 32kHz. Examples of audiograms are shown in FIGURES 1 and 2. 
 
 Induction of hydrops. Guinea pigs were anesthetized as described earlier and 
right-side unilateral endolymphatic hydrops was induced as described by Kimura and 
Schuknecht (1). Briefly, the endolymphatic sac and duct were entered through a 
posterior cranial fossa approach, and a small surgical drill was used to enter and 
obliterate the endolymphatic sac and duct, the remains of which were packed with 
bone wax. All right ears were operated on and all left ears were kept as internal 
controls. Post-operatively sulfonamide antibiotics and one dose of liquid Tylenol 
were included in the drinking water of all animals. 
 
Histology Processing . All animals were sacrificed between 16 and 25 weeks 
post surgery. Animals were deeply anesthetized by administration of pentobarbital 
(33.33mg/kg, IP), xylazine (6.9mg/kg. IM), and ketamine (34.57mg/kg, IM). 
Following induction of deep anesthesia, animals were transcardially perfused with 
normal saline supplemented with heparin (10 units/liter) and sodium nitrite 
(69mg/liter), followed by transcardial perfusion with 10% buffered formalin. Fully 
fixed animals were decapitated and their temporal bones dissected out en-bloc. The 
bullae were opened and the temporal bones were stored fully submerged in 10% 
buffered formalin. After all animals had been sacrificed the temporal bones were sent 
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to the University of Minnesota temporal bone lab where they were decalcified and 
embedded in celloidin. After hardening the specimens were cut into 14 µm sections 
along the mid-modiolar plane. Every 5th slide was mounted and stained with 
Hematoxylin and Eosin for histologic analysis. 
 
Histological Analysis . Quantification of hydrops requires some measure of 
the relative volume of scala media in a hydropic ear compared to a normal ear. The 
most widely used methods for making this determination involve using histological 
morphometry. Two approaches researchers have taken are to either use a ratio of the 
measured length of Reisner’s membrane in a hydropic cochlea to the straight distance 
between its normal lateral and medial attachment points,4 or to directly measure the 
scala media area.11 We chose to take scala media measurements because this more 
directly relates to scala media volume, the true measure of hydrops. 
 
Sections were photographed with a Spot Jr. digital camera (Micro Video 
Instruments, Avon MA) connected to a Nikon TE300 microscope. All image analysis 
was done with MetaView 4.0 (Universal Imaging Corporation, Downington, PA). 
Representative images are shown in FIGURES 3 and 4. Hydrops was determined by a 
modified version of a technique described by Klis et al.10 Every slide where it was 
possible to measure the area of both the scala media (SM) and the scala vestibuli (SV) 
on both sides of the modiolus was studied. In order to determine a relative measure of 
the degree of hydrops in the operated versus the control ear we first calculated a value 
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we refer to as the proportion scala media (PSM). This is simply the proportion of the 
combined SM and SV space that is made up by SM.  In formula: 
 
                                  PSM =                                         SM area SM area + SV area 
SM area  
 
We used this proportional measurement, as suggested by Klis et al. in order to 
compensate for any slight deviations in the plane of section between animals.  The 
measurements taken on each slide were summed to give a measure of the total PSM 
for each cochlear turn. We then calculated a relative measure of hydrops in the 
operated versus the control ear that we refer to as the hydropic ratio (HR). This was 
calculated for each turn by dividing each turn’s total PSM in the right ear by the total 
PSM for the same turn from the left ear.  In formula: 
          
                                   HR = 
Total left ear PSM  
Total right ear PSM  
 
A hydropic ratio of 1 for a given turn would indicate that no hydrops had developed 
in that turn. Likewise, a hydropic ratio of 3 would indicate a 3-fold increase in 
volume in the scala media of a turn in the operated ear compared to the control ear. 
This differs from the technique of Klis et al. in that they took as a measure of hydrops 
the average of 2 representative measurements from each ear. Each measurement they 
used was from the most hydropic turn from a slide that clearly showed all four turns. 
With this technique one develops an overall measure of hydrops, but not one that is 
turn specific. For guinea pig 31 in our study histology for the left ear was inadequate 
to make measurements, so in lieu of measurements from that ear we used an average 
of the area measurements from the left ears of the other eight animals. By taking 
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measurements at all turns our technique allows for generation of both a turn specific 
hydropic ratio and an overall measure of hydrops. The overall measure of hydrops 
was made by averaging all the measurements for each turn in a single animal and then 
normalizing that value to the percentage of the total length of the cochlea made up by 
that turn and then adding the weighted values for each turn. As an alternative method 
we also divided the sum of the measurements taken in the right ear by the sum of the 
measurements taken in the left ear. Because of the different number of sections in 
different turns this inherently weights the measurements. The results were 
indistinguishable.  
 
Determination of cochlear frequency position . To determine if the degree 
of hearing loss at a particular frequency was correlated with the degree of hydrops in 
the turn where that frequency is localized we needed to determine the location on the 
basilar membrane characteristic for the frequencies we tested. This information can 
be obtained from the cochlear frequency-position mapping done by Greenwood.14-15 
Greenwood developed a function that relates characteristic frequencies to a specific 
location along the basilar membrane. This function is CF=A(10ax/L-K), where A, a, 
and K are species specific constants, L is the cochlear length in millimeters, and x is 
the distance in millimeters from the apex of the cochlea. Current accepted values for 
the species specific constants for the guinea pig are: A=350, a=2.1, K=0.85, and 
L=18.5 (15). Since we were starting with known frequencies and wanted to know 
where they would be localized in the cochlea we rearranged the Greenwood function 
to calculate a characteristic location given a specific frequency. The rearranged 
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function is: X=((L)Log(CF + AK)-(L)LogA)/a). Solving for x for the frequencies we 
tested yielded the data in TABLE 1.  
 
We compared these lengths to the distances to the center of each cochlear 
turn. The distance from the base of the cochlea to the midpoint of each turn in the 
scala tympani of guinea pigs has been previously determined by Alec Salt.16 His 
measurements, though, were taken along a different line through the cochlea than 
Greenwood’s. Because of this difference Salt took the full length of the cochlea to be 
16.4 mm rather than the 18.5 mm determined by Greenwood. To compensate for this 
we converted the distance from the base reported by Salt to a percentage of the whole 
cochlear length, which we then multiplied by 18.5. This yields the distance from the 
base to the center of each turn along the basilar membrane. These data are shown in 
TALBE 2. Because the frequencies we tested did not for the most part fall precisely 
mid-turn we used these numbers as a guide to estimate which turns would be most 
involved for each frequency. These data are shown in TABLE 3. 
 
 Hearing thresholds and histological HRs were determined for nine animals. 
Hearing loss at frequencies characteristic of each cochlear turn was correlated with 
HR for each cochlear turn. Additionally a weighted overall measure of hydrops was 
correlated with hearing loss at all 5 tested frequencies. Results of the HR for each turn 
for all animals and the average HR of all animals at each turn are shown in TABLES 
4 and 5. The HR revealed that both apical and basilar turns were found to demonstrate 
the most significant deviations from normal (TABLE 5).  
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The relationship between hearing loss and HR was determined by calculating 
a correlation coefficient between these variables. This was calculated for the 
relationship between hearing loss at all tested frequencies and the HR for each 
individual turn and a weighted overall measure of hydrops. The weighted measure 
was determined by normalizing each turns HR to that turns volume percentage of the 
cochlea. The only statistically significant correlations were found for HR with 2 kHz 
and 16 kHz. These showed a statistically significant relationship to hearing loss in 
both the cochlear turn specific measurements and in the measurement of overall 
hydrops. Interestingly, though, the significant correlation found in the turn specific 
measurements did not arise in the turns most characteristic for those frequencies.    
 
Statistical data summarizing our findings for the correlation between the HR 
in each individual turn and hearing loss are shown in TABLE 6. Only statistically 
significant relationships are shown with a p value. Statistical data summarizing our 
findings for the correlation between weighted whole cochlear hydrops and hearing 
loss are shown in TABLE 7. Again, p values are only given for statistically 
significant results. FIGURES 8 and 9 show representative graphs of significant 
correlations between turn specific HRs and hearing loss and  weighted overall HRs 
and hearing loss respectively. 
 Our histological analysis provides a more thorough estimate of actual scala 
media volume than has been previously reported in animal studies utilizing 
histological techniques. To assess the efficacy of our technique we compared the 
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overall HR ratio calculated using our technique to the overall HR calculated using the 
technique of Klis et al. We then performed a correlation coefficient between the two 
HRs to see if they were statistically different. We could only do this for an overall 
measure of hydrops because Klis et al.’s method does not give turn specific data. 
Guinea pig 31 was not included in the comparison because we had inadequate 
histology in the left ear to duplicate the Klis method. The HRs are shown in TALBLE 
8 and the correlation coefficient in FIGURE 7. These results show no statistical 
difference in the determination of overall hydrops, indicating that our more thorough 
histological analysis offers no advantage in estimating the overall degree of hydrops. 
It does, though, still have the advantage of being able to provide turn specific data on 
hydrops. 
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Discussion 
 
We report for the first time a statistically significant correlation between the 
degree of hydrops and the degree of hearing loss in both low and high frequency 
ranges of guinea pigs with advanced surgically induced endolymphatic hydrops. 
Early reports of surgically induced endolymphatic hydrops as a model for Menière’s 
syndrome report the qualitative relationship between the development of hydrops and 
hearing loss, but offer no statistical analysis.17-18 In 1980 Fraysse et al. reported a 
relationship between hearing loss and a quantitative measure of hydrops from a 
retrospective temporal bone study of humans with Menière’s syndrome. They 
reported a statistically significant correlation between overall degree of hydrops and 
hearing loss at all but the lowest frequencies. Further, they also reported a statistically 
significant relationship between the degree of hydrops in each cochlear turn and the 
hearing loss at the frequency characteristic for that turn for all cochlear turns with the 
exception of posterior middle (0.25 kHz). Since that time there have been a number of 
studies that correlated electrophysiologic measures of hearing with a quantification of 
hydrops in a variety of animal models of Menière’s syndrome.  Taken as a whole this 
work has shown only a weak correlation between the degree of hydrops and the 
amount of hearing loss that develops. 
 
In 1990 Klis et al. reported a statistically significant correlation between 
overall hydrops and decrease in low frequency cochlear microphonics at 29 Hz in 
guinea pigs with surgically induced endolymphatic hydrops.  They quantified hydrops 
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using a histologic approach using two slides per animal, with the most hydropic turn 
on a particular slide taken as a measure of the overall hydrops. They also looked at 
the relationship between degree of hydrops and the summating potential at 2 kHz and 
the action potential at 8 kHz, but found no correlation. We modified their technique 
by taking a measure of hydrops in all sections, and using the aggregate values as a 
measure of turn specific hydrops. This provides a far more extensive histologic 
analysis on which to base our estimates of hydrops. 
 
Klis et al. speculate that the inconsistencies in finding a correlation may be 
due to differing electrophysiologic measures being more or less sensitive to various 
pathologies. While this may be true, it is also worth noting that hearing loss 
associated with endolymphatic hydrops follows a particular clinical course, with loss 
first developing in the lower frequencies, but ultimately progressing across the 
dynamic range. Klis et al. report on data that was pooled from animals sacrificed 2 
and 4 weeks post surgery. This is very early in the development of hydrops, so it is 
possible that a relationship between hearing loss and hydrops may have developed at 
the higher frequencies if the pathology had progressed. Also the guinea pig hearing 
range extends to about 50 kHz, so at a highest frequency of 8 kHz, Klis et al. have not 
reported on the high frequency range. 
 
 In 2000 Bouman et al. reported on the relationship between a histologically 
quantified measure of hydrops and the summating potential at 2 kHz, 4 kHz, and 8 
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kHz in guinea pigs that had hydrops induced by an autoimmune protocol (4). They 
report no statistically significant relationship at any frequency. The measure of 
hydrops they used was an average of measurements taken from the basilar and 
suprabasilar turns in two slides. The middle of the basilar turn has a characteristic 
frequency of about 16 kHz and the suprabasilar turn of about 4 kHz, but they did not 
present this data separately. It is also important to remember that one should be 
careful about comparing these results to those of animals with surgically induced 
endolymphatic hydrops. It is not clear that the pathophysiology of hearing loss will be 
the same. Of particular note is that by six weeks past inoculation the animals in this 
study no longer appear hydropic. This is in striking contrast to surgically induced 
hydrops, which continues in time with progressive hydrops. 
 
Our results show more correlation than previously reported, but still do not 
duplicate the results of Fraysse et al. Why there might be a difference at different 
frequencies remains to be explained, but it is of note that a statistically significant 
relationship was found in the high frequency range, which has previously not been 
reported on. The report by Fraysse et al. was in human temporal bones, and 
correlating the human to an animal model is fraught with difficulties. However, their 
findings of a correlation between hydrops and hearing loss magnitude are to some 
degree recapitulated now in the animal model. The reasons for this are likely 
multifactorial, and include the analysis of cases of advanced hydrops, detailed 
compilation of HR from the whole cochlea, as well as the measurement of hearing 
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changes in the high end of the guinea pig dynamic range. The explanation for why we 
found a correlation at 2000 Hz and 16,000 Hz only is speculative. It possibly relates 
to the manner in which pressure and anatomic changes impart injury or homeostatic 
changes to those particular portions of the cochlea. Whether the mechanism for 
hearing loss in hydrops is pressure related or due to direct mechanical changes 
imparted throughout the cochlea, though remains to be determined.   
 
Our own study could perhaps have given more insight into these relationships 
if we had looked at lower frequencies, or used a better electrophysiological measure, 
such as compound action potentials. Nonetheless, the finding of greater correlation 
between hydrops and hearing loss than previously reported in animal studies has 
possible significance. Beyond working toward validating the common animal model 
this data perhaps sheds some light on appropriate treatment for human patients with 
Menière’s syndrome.  If in fact there is a reasonable correlation between hearing loss 
and the severity of hydrops, regardless of what the pathophysiology might be, this 
reinforces the need to vigilantly apply treatment modalities aimed at reducing 
hydrops. 
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Figure 1: 
Representative audiogram at 16,000 Hz (right ear) from a normal hearing animal 
before surgical obliteration of the endolymphatic duct and sac. Threshold was 
estimated at 35 dB SPL. 
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Figure 2 
Representative audiogram at 16,000 Hz (right ear) 22 weeks after surgical obliteration 
of the right endolymphatic duct and sac in the guinea pig presented in Figure 1. 
Threshold was estimated at 70 dB SPL, with an overall threshold shift of 35 dB SPL.. 
 
 130
 
 
 131
Figure 3 
 
Morphometric analysis of a control (left) ear from guinea pig 35, showing measured 
scala media and scala vestibule areas (200x).
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Figure 4 
Morphometric analysis of the operated (right) ear from guinea pig 35, showing 
measured scala media and scala vestibule areas. Note dilatation of scala media 
indicating severe hydrops (200x). 
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Frequency Distance from the apex 
2000 Hz 7.2 mm 
4000 Hz 9.6 mm 
8000 Hz 12.1 mm 
16000 Hz 14.7 mm 
32,000 Hz 17.3 mm 
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Table 1 
Tested hearing frequencies and their corresponding distance from the apex of the 
cochlea 
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Distance from the 
base measured in 
the scala tympani 
Distanced from the 
apex on the basilar 
membrane 
Percentage from 
the apex Turn 
basilar 2.1 mm 0.88 16.1 mm 
supra-basilar 7.5 mm 0.54 10.0 mm 
sub-apical 11.6 mm 0.29 5.3 mm 
apical 15.1 mm 0.07 1.3 mm 
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Table 2 
 
Conversion of distance from the base to distance from the apex, compensating for 
cochlear path. 
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Frequency Representative turn 
2,000 Hz Turn 3 or Turn 2 
4,000 Hz Turn 2 
8,000 Hz Turn 2 or Turn 1 
16,000 Hz Turn 1 or Turn 2 
32,000 Hz Turn 1 
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Table 3  
Estimated correlation between tested frequency and cochlear turn 
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animal basilar turn 
suprabasilar 
turn subapical turn apical turn 
Gp 17 3.57 2.07 2.39 1.78 
Gp 31 3.53 3.70 3.47 2.36 
Gp 33 1.09 1.04 1.31 2.29 
GP 34 1.75 1.15 1.55 2.60 
Gp 35 4.5 3.31 3.34 2.96 
Gp 36 7.36 4.53 4.32 2.29 
Gp 37 5.76 3.91 3.69 2.72 
Gp 42 1.30 0.86 0.93 1.25 
Gp 51 1.61 1.93 3.52 2.91 
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Table 4 
HR for all animals at all turns 
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turn average hydropic ratio 
Basilar 3.39 
Suprabasilar 2.50 
Subapical 2.72 
Apical 3.35 
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Table 5 
Cochlear turn versus average hydropic ratio (HR) 
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Turn Frequency R2 p 
1 2000 Hz 0.7003 0.0025<p<0.005 
1 4000 Hz 0.3293  
1 8000 Hz 0.0385  
1 16,000 Hz 0.3690  
1 32,000 Hz 0.2204  
2 2000 Hz 0.6731 0.01<p<0.020 
2 4000 Hz 0.2788  
2 8000 Hz 0.0172  
2 16,000 Hz 0.4286 0.025<p<0.05 
2 32,000 Hz 0.1555  
3 2000 Hz 0.4450 0.025<p<0.05 
3 4000 Hz 0.2535  
3 8000 Hz 0.0164  
3 16,000 Hz 0.5459 0.01<p<0.02 
3 32,000 Hz 0.154  
4 2000 Hz 0.1769  
4 4000 Hz 0.0281  
4 8000 Hz 0.0296  
4 16,000 Hz 0.0459  
4 32,000 Hz 0.00003  
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Table 6 
 
Statistical data summarizing the correlation between the HR in each individual turn 
and hearing loss at the frequencies represented at those turns. Only statistically 
significant relationships are shown with a p value. 
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Frequency R2 p 
2000 Hz 0.7433 0.005<p<0.01 
4000 Hz 0.3265  
8000 Hz 0.0293  
16,000 Hz 0.6590 0.025<p<0.05 
32,000 Hz 0.2046  
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Table 7 
 
Whole cochlea hydrops correlations with frequency. 
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Figure 5 
 
Statistically significant correlation between the HR in the basilar turn and hearing 
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Figure 6 
 
Statistically significant correlation between a weighted overall measure of HR and 
hearing loss at 2 kHz 
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Animal HR (Klis) HR (Hott) 
gp17 2.81 3.52 
gp33 1.22 2.36 
gp34 1.63 1.63 
gp35 3.84 3.40 
gp36 5.62 7.06 
gp37 4.63 8.44 
gp42 1.11 1.00 
gp51 2.18 3.70 
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Table 8  
 
Comparison of overall HR calculated by counting all possible cochlear areas (Hott)  
and 2 representative areas per ear (Klis) 
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Hott Overall Hydropic Ratio Vs. Klis Overall 
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Figure 7 
 
Correlation of  Hott HR to Klis HR, showing no statistical difference between the two 
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CHAPTER 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AMINOGUANIDINE ADMINISTRATION AND HEARING 
PRESERVATION IN EXPERIMENTAL ENDOLYMPHATIC 
HYDROPS IN THE ALBINO GUINEA PIG  
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Abstract 
 
 
 Objectives/Hypothesis. The goal of the current study was to evaluate the 
pharmacologic potential of aminoguanidine, a relatively specific inhibitor of the 
inducible isoform of nitric oxide synthase (iNOS), to protect against hearing loss in 
guinea pigs with surgically induced endolymphatic hydrops, the standard animal 
model for Menière’s syndrome.  
 
 Methods. Right sided endolymphatic hydrops was surgically induced in 20 
guinea pigs. Half were administered aminoguanidine in their drinking water for 22 
weeks. Hearing thresholds were measured by auditory brainstem response (ABR) 
approximately every 2 weeks, and thresholds in treated and untreated animals were 
compared at 2 kHz, 4 kHz, 8 kHz, 16 kHz, and 32 kHz.  
 
 
 Results. Hearing was preserved in all unoperated ears and declined in all 
operated ears, though this was not statistically significant at 4 kHz and 8 kHz in the 
aminoguanidine treated group. Overall there was a statistically significant 
preservation of hearing in the treated verse the control group at all tested frequencies 
by 16 weeks.  
 
 Conclusions. Aminoguanidine appears to provide a neuroprotective effect in 
the hydropic cochlea that prevents hearing loss in animals with surgically induced 
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endolymphatic hydrops. These results are encouraging, and merit additional study to 
investigate the possibility of a hearing protective therapeutic intervention in humans. 
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Introduction 
 
 
 Menière’s syndrome is a disorder that is characterized by idiopathic 
endolymphatic hydrops, with associated progressive sensorineural hearing loss and 
periodic tinnitus and vertigo. The reported incidence of Menière’s syndrome in 
Europe and the United states has ranged from 7.5-157 per 100,0001-2. Menière’s 
syndrome most commonly presents in patients 40-60 years of age with a slight 
increased incidence in women compared to men3. It typically presents initially with 
symptoms affecting a single ear, but can progress to involve the contralateral ear as 
well. Reports of the frequency of progression to the contralateral ear have varied 
widely, ranging from 2-78%4. It has been proposed that this unusually large range is 
probably related to differing diagnostic criteria and length of follow up, with the true 
value being closer to the higher end of the range5.   
 
 Endolymphatic hydrops, somewhat analogous to edema of the inner ear, is a 
condition characterized by expansion of the scala media by excess endolymph. In 
principal this can be due to either an overproduction of endolymph or a lack of 
resorption of endolymph. However, it is not currently known whether overproduction, 
insufficient resorption, or a combination of these mechanisms is responsible for the 
findings in Menière’s syndrome7. Further, while there is a well established 
association between endolymphatic hydrops and the clinical symptoms of Menière’s 
syndrome, the mechanism by which this occurs is still a matter of speculation. The 
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continued lack of understanding of the pathogenesis of Menière’s syndrome is in part 
due to a lack of understanding the basic mechanisms involved, but also, I suspect, 
reflects that the pathogenesis of the ubiquitous endolymphatic hydrops is likely 
multifactorial. 
 
 Recent studies have demonstrated a selective destruction of type II ganglion 
cells in the cochlea of guinea pigs with surgically induced endolymphatic hydrops, 
with a nearly complete sparing type I ganglion cells8. Exactly why this occurs is 
unknown, but one reasonable speculation is that because of their different anatomic 
associations type II ganglion cells are more susceptible to neurotoxic damage. While 
Type 1 ganglion cells are completely enveloped by the afferent nerve ending of the 
calyx, type II ganglion cells are bathed in perilymph at their basal and lateral surfaces, 
and thus are far more vulnerable to neurotoxic damage from the surrounding 
environment. It has also been reported that the inducible isoform of nitric oxide 
synthase (iNOS) is found in high levels in the hydropic cochlea, but not in the normal 
cochlea9-10. We postulate that excessive nitric oxide may be the neurotoxic culprit 
responsible for much of the damage in the hydropic cochlea. To test this theory we 
administered aminoguanidine, a relatively specific inhibitor if iNOS11-13, to a cohort 
of guinea pigs with surgically induced endolymphatic hydrops. In this animal model 
of Menière’s syndrome there is a characteristic sensorineural hearing loss that takes 
place. We hypothesize that if nitric oxide is indeed part of the pathology leading to 
hearing loss in Menière’s syndrome, then inhibiting the formation of nitric oxide 
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should be protective against hearing loss, even in the presence of hydrops. To test this 
theory we used auditory brain stem response (ABR) to monitor hearing thresholds 
along a range of frequencies in aminoguanidine treated guinea pigs with surgically 
induced endolymphatic hydrops, the standard animal model for Menière’s syndrome. 
To date we are not aware of any studies demonstrating pharmacological hearing 
protection in Menière’s syndrome. 
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Methods and Materials 
 
 Materials. The study was carried out using 20 albino guinea pigs (Duncan 
Hartley strain) each initially weighing 250-300 grams. All guinea pigs obtained from 
the Charles River Breeding Labs (Wilmington, MA). Prior to hearing tests, guinea 
pigs were anesthetized by administration of pentobarbital (16.67mg/kg, IP), xylazine 
(3.46mg/kg. IM), and ketamine (17.28mg/kg, IM). Body temperature was maintained 
with an electric heating pad (Harvard Apparatus, Holliston, MA). Aminoguanidine 
was purchased from Sigma Aldrich (Irvine, Ca). All animals were treated in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals, and the 
protocol was approved by the Animal Care Committee at the University of 
Massachusetts Medical School. 
 
Induction of hydrops . Guinea pigs were anesthetized as described earlier and 
right-side unilateral endolymphatic hydrops was induced in the usual manner as 
described by Kimura and Schuknecht14. Briefly, the endolymphatic sac and duct were 
entered through a posterior cranial fossa approach, and a small surgical drill was used 
to enter and obliterate the endolymphatic sac and duct, the remains of which were 
packed with bone wax. All right ears were operated on and all left ears were kept as 
internal controls. Post-operatively sulfonamide antibiotics and one dose of liquid 
Tylenol were included in the drinking water of all animals. 
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Hearing Tests . All hearing thresholds were obtained using Intelligent Hearing 
Systems’ Auditory Brainstem Response (ABR) system, version 3.6x (Intelligent 
Hearing Systems, Miami, Fl). Sound was introduced through a custom made sound 
source described in detail elsewhere15. Briefly, the sound source, which consisted of a 
Radio Shack 40-1377 ‘Super Tweeter’ high-frequency dynamic speaker, a brass ear 
bar to direct sound into the ear canal, and a coupler to attach the ear bar to the 
speaker, was fit securely into the external auditory canal of the guinea pig. Grass 
subdermal needle electrodes were placed at the midline scalp and retroauricularly. 
Electrical activity was amplified 100,000 times and was filtered (0.1-3 kHz) with a 
bioamplifier. The signal was digitized by an MII signal averaging system and an IBM 
PC clone. Each response was the average of 1024 sweeps presented at a rate of 19.3 
Hz and was stored on the PC clone. Threshold of hearing was determined to plus or 
minus 5 dB SPL for frequencies of 2 kHz, 4kHz, 8kHz, 16kHz, and 32kHz. 
 
Aminoguanidine Administration . Twenty female guinea pigs were operated 
on to surgically induce right-sided unilateral endolymphatic hydrops. Ten of these 
animals were treated with aminoguanidine in their drinking water for twenty-two 
weeks. The remaining ten animals were left as untreated controls. The 
aminoguanidine in the drinking water was added at 2.0 grams per liter, and the 
animals were allowed free access to the water. All animals were caged individually, 
and hearing tests in both ears on all animals were performed approximately every 2 
weeks.   
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Statistical Analysis . Difference in mean hearing thresholds between 
experimental and control groups for each measured frequency at each time point was 
analyzed by one way analysis of variance (ANOVA) with Tukey post hoc multiple 
comparisons. 
 
 Statistical significance between mean starting and ending hearing thresholds 
in treated and control animals in both ears was determined by paired sample t test.  
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Results 
 
 
Aminoguanidine Tolerance . All animals appeared to tolerate 
aminoguanidine well, without obvious ill effect. After 22 weeks there was no 
significant difference in weights between the treated and untreated animals (Figure 1). 
This is consistent with previous reports of the use of aminoguanidine in experimental 
animals in which there have been no reported effects on weight, renal, or 
cardiovascular health.13, 16-17
 
 
Hearing Thresholds . Hearing thresholds for all animals were determined at 
2kHz, 4kHz, 8kHz, 16kHz, and 32kHz from start to twenty-two weeks. Hearing was 
unaltered over time in all unoperated ears (Figures 2-3). Hearing thresholds increased 
in all operated ears (Figure 4-5), though this did not reach statistical significance at 4 
kHz and 8 kHz in aminoguanidine treated animals. There was a statistically 
significant prevention of hearing loss in the operated ears of treated verse control 
animals at all frequencies by 16 weeks (Figures 6-10).   
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Discussion 
 
 
 Excessive production of nitric oxide related to increased levels of iNOS has 
been shown to be cytotoxic in many tissues and neurotoxic in the central nervous 
system18. We have hypothesized that the characteristic sensorineural hearing loss seen 
in Menière’s syndrome may be related to a neurotoxic injury from elevated levels of 
nitric oxide in the inner ear. The goal of the current study was to evaluate the 
potential of aminoguanidine, a relatively specific iNOS inhibitor, as a pharmacologic 
neuroprotective agent for the preservation of hearing in albino guinea pigs with 
surgically induced endolymphatic hydrops, the standard animal model for Menière’s 
syndrome.  
 
 In the current study the aminoguanidine treated animals had statistically 
significant protection against hearing loss. We interpret these results to indicate that 
neuroprotection by pharmacological inhibition of iNOS was partially protective 
against hearing loss in the standard animal model of Menière’s syndrome.  
 
 There are some limitations of this study that will need to be addressed in 
future work. The amount of treated water consumed by guinea pigs was not 
measured, leaving it unclear how much aminoguanidine was administered. Further 
study in this area should attempt to quantify a dose response. Also, it will be 
important to look for histologic and immunohistochemical correlations to hearing 
protection in the cochlea of treated animals to help substantiate the mechanism by 
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which aminoguanidine is protective. Ultimately, if these promising results continue, 
this work may suggest a possible therapeutic treatment for humans. While it is 
premature to consider human trials with aminoguanidine for hearing preservation in 
Menière’s syndrome, it is worth noting that the hurdle to beginning human trials is 
not as onerous as it might be, as aminoguanidine has already been used in FDA 
approved human studies19.  
 
 
 
 
 
 
 168
References 
 
 
1. Peron DL, Kitamura K, Carniol PJ, Schuknecht HF. Clinical and experimental  
    results with focused ultrasound. Laryngoscope 1983; 93:1217–1221. 
 
2. Wladislavosky-Waserman P, Facer GW, Bahram M, Kurland LT. Menière’s  
    disease: a 30-year epidemiologic and clinical study in Rochester, MN, 1951– 
     1980. Laryngoscope 1984; 94:1098–1102. 
 
4. Kitahara M. Bilateral aspects of Menière’s disease: Menière’s disease with   
    bilateral fluctuant hearing loss. Acta Otolaryngol (Stockh) 1991; 485:74–77. 
 
5.  Balkany TJ, Sires B, Arenberg IK. Bilateral aspects of Menière’s disease: an  
     underestimated clinical entity. Otolaryngol Clin North Am 1980; 13:603–609. 
 
6. Balkany TJ, Sires B, Arenberg IK. Bilateral aspects of Menière’s disease: an  
    underestimated clinical entity. Otolaryngol Clin North Am 1980; 13:603–609. 
 
7. Paparella MM. The cause (multifactorial inheritance) and pathogenesis  
    (endolymphatic malabsorption) of Menière’s disease and its symptoms  
    (mechanical and chemical). Acta Otolaryngol (Stockh) 1985; 99:445–451. 
 
 
 169
8. Tsuji, KL, Velazques-Villasenor, SD, Rauch, et al. Temporal bone studies of  
    the human peripheral vestibular system: Meniere’s disease. Ann. Otol. Rhinol.  
   Laryngol 2000; 109 (Pt. 2, Suppl. 181): 26–31. 
 
9. Hess A, Bloch W, Su J, Stennert E, Addicks K, Michel O. Expression of  
    inducible nitric oxide-synthase in the vestibular system of hydropic guinea  
    pigs. Neuroscience Letters 1999 Apr 2;264(1-3):145-8.  
 
10. Michel O, Hess A, Su J, Bloch W, Stennert E, Addicks K Expression of  
      inducible nitric oxide synthase (iNOS/NOS II) in the hydropic cochlea of  
      guinea pigs. Hearing Research 2000 May;143(1-2):23-8.  
 
11. Bryk, R and Wolff, DJ. Mechanism of Inducible Nitric Oxide Synthase  
      Inactivation by Aminoguanidine and L-N6-(1-Iminoethyl) lysine Biochemistry  
      1998 37;4844–4852.  
 
12. Brenner, T, Brocke, S, Szafer, F, Sobel, R A, Parkinson, J F, Perez, DH, and   
      Steinman, L. Inhibition of nitric oxide synthase for the treatment of  
      experimental autoimmune encephalomyelitis.  Journal of Immunolog  
     1997;158:2940–2946. 
 
13. Waz, W R, Van Liew, JB and Feld, LG. Nitric oxide-inhibitory effect of  
 
 170
      aminoguanidine on renal function in rats. Kidney Blood Pressure Research  
     1997 20;211–217. 
 
14. Kimura RS, Schuknecht JF. Membranous hydrops in the inner ear of guinea  
       pig after obliteration of the endolymphatic sac. Pract Otorhinolaryngol  
       1965; 27:343-5.  
 
15. Greenwood DD. A cochlear frequency-position function for several species:  
      29 years later. J Acoustical Society of America 1990; 87(6):2592-2605. 
 
16. Selles-Navarro I, Villegas-Perez MP, Salvador-Silva M, Ruiz-Gomez JM and  
      Vidal-Sanz M. Retinal ganglion cell death after different transient periods of  
      pressure-induced ischemia and survival intervals. A quantitative in vivo study.  
      Investigative Ophthalmoogy and Visual Scienes 1996; ( 37): 2002–2014. 
 
17. Turner, CH, Owan, I, Jacobs, DS, McClintock, R. and Peacock, M. Effects of  
      nitric oxide synthase inhibitors on bone formation in rats Bone 1996;(  
      21):487–490. 
 
18. Dawson, VL & Dawson, TM. The Ginkgo biloba extract (EGb 761) provides   
      a neuroprotective effect on retinal ganglion cells in a rat model of chronic  
      glaucoma Proc. Soc. Exp. Biol. Med. 1996; 211, 33–40. 
 
 
 171
19. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K,  
      Mooradian AD, Spinowitz BS. Design and baseline characteristics for the  
      aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy  
      Controlled Clinical Trials. 1999 Oct; 20(5):493-510.  
 
 172
 
Guinea Pig Weights (mean ± sd) 
Treated Initial 273 grams ± 28 grams 
Treated Final 1027 grams ± 128 grams 
Control Initial 285 grams ± 18 grams 
Control Final 1018 grams ± 115 grams 
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Figure 1 
 
Beginning and ending mean guinea pig weights in grams ± sd.  
 
 174
 
Mean Difference in Starting and Ending Hearing  
Thresholds in Untreated Animals in Non-Hydropic Ears 
Frequency Initial (dB SPL) Final (dB SPL) Difference (dB SPL)  
***2 kHz 35.4 ± 3.1 37.1 ± 2.3 +1.9 
***4 kHz 36.2 ± 2.1 35.1 ± 4.2 - 0.9 
***8 kHz 18.7 ± 4.2 20.3 ± 3.3 +1.6 
***16 kHz 20.1 ± 5.2 18. 1± 4.5 -2.0 
***32 kHz 21.6 ± 4.4 25. 3 ± 5.3 +3.7 
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Figure 2 
 
Difference between initial and final mean hearing thresholds in the unoperated, 
control ear of untreated animals. *** signifies lack of statistical significance, with 
p>0.05.  
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Mean Difference in Starting and Ending Hearing  
Thresholds in Treated Animals in Non-Hydropic Ears 
Frequency Initial (dB SPL) Final (dB SPL) Difference (dB SPL)  
***2 kHz 33.4 ± 3.9 35.1 ± 4.1 +1.7 
***4 kHz 31.2 ± 9.4 36.3 ± 6.2 +5.1 
***8 kHz 20.2 ± 3.7 16.4 ± 5.0 -3.8 
***16 kHz 16.0 ± 8.3 19. 3± 5.1 +3.3 
***32 kHz 20.9 ± 4.4 23. 1 ± 7.1 +2.2 
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Figure 3 
 
Difference between initial and final mean hearing thresholds in the unoperated, 
control ear of treated animals. *** signifies lack of statistical significance, with 
p>0.05.
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Mean Difference in Starting and Ending Hearing  
Thresholds in Untreated Animals in Hydropic Ears 
Frequency Initial (dB SPL) Final (dB SPL) Difference (dB SPL)  
2 kHz 38.8 ± 3.8 61.3 ± 2.3 +21.5 p<0.01 
4 kHz 35.6 ± 3.2 57.5 ± 4.2 +21.9 p<0.01 
8 kHz 16.3 ± 4.4 42.5 ± 3.3 +26.2 p<0.01 
16 kHz 18.8 ± 4.5 52.5 ± 8.2 +33.7 p<0.01 
32 kHz 20.6 ± 5.6 45.0 ± 4.5 +24.4 p<0.01 
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Figure 4 
 
Difference between initial and final mean hearing thresholds in the operated ear of 
untreated animals. 
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Mean Difference in Starting and Ending Hearing  
Thresholds in treated Animals in Hydropic Ears 
Frequency Initial (dB SPL) Final (dB SPL) Difference (dB SPL)  
2 kHz 37.5 ± 3.3 45.0 ± 6.3 +7.5 p<0.05 
4 kHz 36.9 ± 3.7 42.5 ± 5.3 +5.6 *** 
8 kHz 19.6 ± 7.5 24.4 ± 6.1 +4.8 *** 
16 kHz 20.5 ± 4.9 32.5 ± 6.9 +12 p<0.05 
32 kHz 23.8 ± 3.3 31.3 ± 2.1 +7.5 p<0.05 
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Figure 5 
 
Difference between initial and final mean hearing thresholds in the operated ear of 
treated animals. *** signifies lack of statistical significance, with p>0.05. 
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Figure 6 
 
Mean hearing thresholds at 2 kHz in aminoguanidine (AG) treated and untreated 
controls (CT). The difference between the means was statistically significant from 16 
weeks on (p < 0.05). 
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Figure 7 
 
Mean hearing thresholds at 4 kHz in aminoguanidine (AG) treated and untreated 
controls (CT). The difference between the means was statistically significant from 16 
weeks on (p < 0.05). 
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Figure 8 
 
 
Mean hearing thresholds at 8 kHz in aminoguanidine (AG) treated and untreated 
controls (CT). The difference between the means was statistically significant from 16 
weeks on (p < 0.05). 
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Figure 9 
 
Mean hearing thresholds at 16 kHz in aminoguanidine (AG) treated and untreated 
controls (CT). The difference between the means was statistically significant from 16 
weeks on (p < 0.05). 
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Figure 10 
 
Mean hearing thresholds at 32 kHz in aminoguanidine (AG) treated and untreated 
controls (CT). The difference between the means was statistically significant from 16 
weeks on (p < 0.05). 
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Discussion 
  
 The goals of the cartilage tissue engineering research presented here were 
three-fold: first, to establish the chondrogenic potential of adult human nasal septal 
chondrocytes; second, to demonstrate the formation of small calcium alginate 
constructs in complex geometries with high dimensional tolerances utilizing 
computer-aided design and an injection molding process; and finally, to establish that 
calcium alginate can be reliably modified by the efficient covalent addition of 
peptides, and that by adding a TGF-β binding peptide we could alter the release 
characteristics of pre-loaded TGF-β1 from a molded alginate gel.  
 
 The data presented in this thesis are encouraging with regards to all the stated 
goals. As such, the work of this thesis helps to highlight the exciting potential of 
cartilage tissue engineering. We have shown that adult human nasal septal 
chondrocytes have substantial chondrogenic potential when grown within an alginate 
scaffold.  We have shown that alginate is a versatile polymer for cartilage tissue 
engineering purposes, amenable to both precise shaping and modification by covalent 
addition of peptides, which, in principle, could serve any number of biologically 
important functions.  
 
 Even in light of these encouraging results, though, perhaps this work should 
also serve as a somewhat sober reminder that the field of tissue engineering is still in 
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its infancy. While the work presented here is encouraging, it is by no means 
definitive. Truly definitive work in cartilage tissue engineering should not only 
demonstrate a clinically useful method for engineering a replacement cartilage 
indistinguishable from healthy native cartilage, but should also show that the 
engineered cartilage performs in humans like healthy native cartilage for many years.  
 
 Our results are indeed encouraging, but they stem from looking at one cell 
source with one scaffold in one set of growth conditions. Seen in the context of the 
veritable panoply of well studied scaffolds, numerous cell sources, and abundant 
culture conditions, it is not possible to know how our results would compare to the 
innumerable rich opportunities that remain uninvestigated. This is part of both the 
excitement and the frustration of working in an emerging field.  
  
 A critical appraisal of the tissue engineering literature reveals the existence of 
many novel and promising biologically-based approaches for the induction of 
articular cartilage repair, the vast majority of which are still at an experimental phase 
of development. There are, however, no prospective, double-blinded clinical trials 
showing the efficacy of cartilage tissue engineering. The tissue engineering 
approaches to articular cartilage repair thus far pursued have been principally of an 
empirical nature and still very much at an experimental stage of development. From a 
clinical standpoint, where only definitive solutions count, results achieved to date are 
far from satisfactory with respect to repair tissue quality and durability. Success in the 
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future depends upon our now following a rational, rigorous approach to the problem, 
based on biological principles at the molecular, cellular and physiological levels.  
  
 Although it has been suggested many times that the problems of tissue 
engineering should be thought of as a recapitulation of embryological differentiation, 
this is probably not a particularly good idea.1-3 Both the cellular microenvironments 
and tissue macroenvironments encountered in adult organisms are fundamentally 
different from those encountered in embryological environments. Apart from the 
signaling molecules, which are most probably the same, every other component is 
different, including the existence of an active immune system in fully-developed 
organisms. Thus, while the control available with in vitro systems is appealing, the 
attempt to engineer complete constructs, consisting of a matrix, cells, and bioactive 
signaling molecules in vitro, with the thought that terminal differentiation will occur 
after in situ implantation, may be overly optimistic, especially when we consider the 
mammalian body’s own limited tissue engineering capacity, as exemplified by scar 
formation.  
 
 Future tissue engineering studies will need to tackle an often overlooked 
issue; namely, tissue integration. A tissue engineered construct must be accepted by, 
and become integrated with, tissue neighboring its destined site without triggering the 
immunological responses that would result in its resorption. Following resorption, it 
would inevitably be replaced by a scar-like or fiber-rich tissue bearing little 
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resemblance to the articular cartilage we all aspire to make. If the engineered 
constructs are reabsorbed and exchanged following their implantation, then the great 
pains we have gone to in order to created the conditions conducive to cartilage 
development and growth will be in vain. Additionally, as we move forward in the 
next generation of cartilage tissue engineering experiments we will need to pay more 
attention to recreation of the zonal organization in native collagen. To date 
engineered cartilage has been homogeneous, but if an engineered construct is to fill a 
full thickness defect, or even replace an entire articular surface it should be 
engineered to replicate the zonal architecture in native cartilage. This will require 
continued enhancement of our understanding of the differing molecular biology and 
gene expression of chondrocytes in different cartilage zones.  
 
 Part of the great challenge in moving forward in tissue engineering is the 
incredible complexity that arises when considering that a successful application will 
need to consider appropriate use of cells, polymers, and growth factors. Each of these 
individually is legitimately an enormous puzzle. When one starts to consider 
combining these issues, the magnitude of the problem increases exponentially. 
Certainly, the same matrix may not be appropriate for use with all tissues, and of 
course, different cell types may behave differently in different matrices. Best results 
may be achieved with three or more matrices in a single construct, but the more we 
start combining elements the more difficult a rigorous analysis becomes.  
 
 
 196
 The potential and promise of tissue engineering to change the face of 
medicine is enormous. After all, in its ideal form it promises nothing less than the 
replacement of damaged or unhealthy tissue with a replacement, indistinguishable 
from healthy native tissue. Do you have osteoarthritis? Stop taking 
antiinflammatories, we will make you new, healthy, gleaming articular cartilage, like 
you had in your youth. Do you have hepatic cirrhosis? No need to wait for a 
transplant, we can make you a new liver. Do you have diabetes? Close the dialysis 
centers, we can make you new kidneys. Let’s face it, to the degree that science can be 
sexy, this is awfully sexy stuff.  
 
 Given its revolutionary potential, it should come as no surprise that tissue 
engineering makes good press. When I was working on my thesis research, I 
appeared on the evening news (in the background) for ABC, CBS, NBC, the BBC, 
and the Discovery Channel. For the year 2000 change of the millennium edition, 
Time Magazine predicted “tissue engineer” as the number one occupation for the 
twenty first century. There was a period of time when the work of our lab was so 
often in the news when people in pain and need would contact the lab on a nearly 
daily basis, asking if we could help. They would volunteer to have new tissues 
implanted, without really understanding what we were doing. From the evening news, 
to the popular press, to the general public, tissue engineering has captured our 
imagination. 
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 For those who work in this field, though, we must always remember that the 
devil is in the details, and we must remain cautious, and skeptical. The project that 
truly caught the attention of the world was the work of Vacanti et al in which an 
engineered cartilage human ear was grown on the back of an athymic mouse.4 The 
press coverage was enormous, and forever changed the public perception of tissue 
engineering in medicine. And it probably does not even bear saying, but the public, 
whether they supported or decried the work, did not really understand what was done. 
This project like much of the work of tissue engineering was proof of principal. It 
demonstrated in broad strokes what the future might hold. As the field has continued 
to grow the real, slow, incremental work of advancing this new science has begun. 
And the truth is that from a basic science standpoint we are at the very beginning of 
understanding how a new tissue might be engineered. What is the best matrix to use? 
What is the best cell source to use? How should growth factors be delivered? Should 
we use gene therapy or encapsulate the needed growth factors in a polymer scaffold? 
Many researchers around the world, certainly more than ever before in history, are 
working toward answering these questions, but still it would be terribly premature to 
claim sure answers. No one has yet cured diabetes, osteoarthritis, or any other ailment 
by applying engineered tissues, so for some the blush of tissue engineering has begun 
to fade. In my opinion, this perception is really for the best. Too much publicity is not 
necessarily a good thing. 
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 Tissue engineering is a field still in its infancy, and perhaps it is having some 
growing pains. Much of the work to date has painted with a broad brush. It has been 
empirical in nature, and largely about proof of principal. As the field is now maturing 
the time has come to get down to the detailed work of molecular biology, physiology, 
engineering, and gene therapy. It is time to begin the slow process of answering the 
detailed questions that will allow for the incremental progress of science, and I 
believe that is what we are now seeing in tissue engineering. Certainly the promise of 
tissue engineering will always fire the imagination of those who work in this field, 
but on a daily basis the question should not be “when can we make a tissue that 
serves all the functions of native tissue?”, but rather “what gene is being expressed?”, 
“how can I make this matrix stiffer?”, “what is the Kd of this ligand”. It is through the 
rigorous application of science to an endless number of small detailed questions that 
we will ultimately pool the data to answer the big picture questions that have 
captivated so many. 
 
 Tissue engineering has also begun to come up against the harsh realities of 
clinical medicine. This science is part of medical science, which is to say that the 
ultimate goal must be to produce useful products to improve human health. In some 
cases this calls into question the value of the project as a whole. While there is 
something aesthetically and intellectually appealing about creating, de novo, a new 
articular surface for a knee devastated by osteoarthritis, to make this a realistic project 
we also need to show that it is the best treatment we can offer. Meaning, if we can 
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make an artificial knee that provides relief from pain and adequate mobility, do we 
really need to be making new cartilage? As a reality check, we should recognize that 
making replacement tissues will almost certainly be substantially more expensive 
than making synthetic replacements. Making tissues requires the use of cells and 
bioactive molecules, which by necessity requires manufacturing in a sterile 
environment. Medical devices, on the other hand, containing no biological elements, 
are manufactured in a clean environment and the final product is subsequently 
sterilized. This difference in processing alone can increase costs by an order of 
magnitude.5 Add to this the complexity and cost of using living cells and large 
quantities of growth factors, and it is clear that any tissue engineered product will 
need to be clearly superior to any synthetic product to have any hope of becoming 
part of mainstream medical practice.  
 
 At this time, the existence of so many new and encouraging biological 
approaches to cartilage repair still justifies the future investment of time and money 
in this research area, particularly given the extremely high socio-economic 
importance of therapeutic strategies in the prevention and treatment of common joint 
diseases. Reaching the stage where we are ready for clinical trials, even for very small 
applications, will have to come in the not too distant future in order to continue the 
scientific appraisal of current therapies and future novel approaches.   
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 One of my own projects, the tissue engineered tympanic membrane patch, was 
funded for initial animal testing by the world’s largest ENT company, Gyrus ENT. 
The results were good, excellent in fact, but in the end the project stalled, as so many 
others of its kind recently have, as the reality of the difficulty and cost of production 
became clearer. Still, I remain enthusiastic about tissue engineering. For the benefit of 
the field, though, I believe it is high time that we take tissue engineering off the 
evening news and leave it in the lab where it belongs. It is only there that the slow 
incremental work of science can happen. And slowly, as the small contributions from 
many labs around the world enter the scientific arena, we will begin to uncover 
answers. Will we every truly be able to make new cartilage, a new liver, or any other 
tissue one can imagine? Maybe, but truthfully, I think it is time we stopped asking 
that question, if only for a short time. That question belongs to the era when tissue 
engineering was a grand idea, the era when simple experiments fired the imagination 
with amazing possibilities. I believe that time has passed. Tissue engineering is still a 
new field, but now it is maturing, it is growing up. The work is worth doing. It is 
valid science, and its researchers are doing their small part to increase knowledge. 
And as with all such endeavors it is unclear where our work will ultimately lead until 
we arrive. After all, the role of serendipity in good science, from the work of 
Alexander Flemming to the work of Craig Mello, cannot be overlooked. Pursing 
tissue engineering with detail minded, rigorous science will produce interesting and 
valuable results. We will learn about principles of molecular biology, and the detailed 
nature of many tissues. And perhaps, one day, we really will replace our old tissues 
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like we replace our old car parts. The field of tissue engineering is just getting started, 
just finding its feet. And I for one look forward to seeing how this story unfolds.    
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